![]() |
![]() |
![]() |
![]() |
PB-002 | Effect of switching from well-controlled vitamin K antagonists to a direct oral anticoagulant for atrial fibrillation on quality of life: little to GAInN | Jasper H.A. van Miert | ![]() |
![]() |
|||
PB-003 | Real-life anticoagulant treatment with edoxaban in patients with atrial fibrillation and venous thromboembolism: subanalysis of patient with creatinine clearance greater than 95 ml/min. Experience of 26 months in our centre | Pablo Romero Garcia | ![]() |
![]() |
|||
PB-004 | Comparison of peak and trough concentrations of dabigatran, rivaroxaban and apixaban with the published expected values in patients with non valvular atrial fibrillation | Sandra Margetic | ![]() |
![]() |
|||
PB-005 | The impact of an educational intervention in patients with atrial fibrillation treated with warfarin: protocol of a clinical trial | Luci Dusse | ![]() |
![]() |
|||
PB-006 | Oral Anticoagulant Therapy in Patients with Atrial Fibrillation and Flutter in Macedonia | Rada Grubovic Rastvorceva | ![]() |
![]() |
|||
PB-009 | Efficacy of immunomodulatory therapy for atherosclerosis-role of tolerance and protective antibodies | Xinjie Lu | ![]() |
![]() |
|||
PB-011 | Immunization with recombinant atherogenic antigen (AHC) does not promote melanoma cell-induced lung cancer In B6;129s-Ldlrtm1herApobtm2sgy/J mice | Xinjie Lu | ![]() |
![]() |
|||
PB-012 | THE PREVALENCE AND GENETIC BASIS OF SITOSTEROLEMIA IN A GROUP OF TURKISH PATIENTS | Zuhre Kaya | ![]() |
![]() |
|||
PB-014 | Biochemical and Hemostatic Predictors of Asymptomatic Carotid Atherosclerosis | Kostiantyn Stepanchenko | ![]() |
![]() |
|||
PB-018 | Large-scale screening for membrane protein interactions involved in platelet-monocyte interactions | Yi Sun | ![]() |
![]() |
|||
PB-030 | Current Status of Lipid-lowering Therapy and Low-density Lipoprotein Cholesterol Goal Achievement in Hospitalized Acute Coronary Syndrome Patients in Fuzhou, China: A Retrospective Real World Study | Hongxin Zhao | ![]() |
![]() |
|||
PB-032 | Free Ubiquitin Attenuates Myocardial Ischemia-reperfusion Injury by Inhibiting Cardiomyocyte Apoptosis and Inflammatory Response | Jialu Yao | ![]() |
![]() |
|||
PB-034 | Current Status of Korea Acute Myocardial Infarction Registry | Myung Ho Jeong | ![]() |
![]() |
|||
PB-035 | Role of Phospholipase D in processes of myocardial healing after myocardial ischemia and reperfusion injury in mice | Meike Klier | ![]() |
![]() |
|||
PB-036 | High prevalence of inherited thrombophilia and antiphospholipid syndrome in myocardial infarction with non-obstructive coronary arteries: comparison with cryptogenic stroke | Anetta Undas | ![]() |
![]() |
|||
PB-040 | Microparticles: An Initiator of Thrombosis: The 18500 Feet Martse Mik la Experiment | Prosenjit Ganguli | ![]() |
![]() |
|||
PB-042 | NEW GENERATION FLOW-CYTOMETRY TO MEASURE CIRCULATING MICROVESISCLES IN CANCER | Elena Campello | ![]() |
![]() |
|||
PB-043 | Major histocompatibility complex class I related chain A/B positive microparticles associate with severity of acute coronary syndrome | Songpol Haohan | ![]() |
![]() |
|||
PB-044 | Endothelial- and monocyte-derived microparticles associate with the presence of acute coronary syndrome | Nantarat Komanasin | ![]() |
![]() |
|||
PB-045 | Phospholipid-dependent procoagulant activity and risk of venous thrombosis in patients with lower-leg injury or knee arthroscopy | Carolina Eveline Touw | ![]() |
![]() |
|||
PB-046 | Platelet microparticles containing microRNA as a marker of the antiplatelet therapy´s effectiveness | Olga Sirotkina | ![]() |
![]() |
|||
PB-049 | The Therapeutic Potential of Heparin-binding Copolymer as an Inhibitor of Heparan Sulfate | Andrzej Mogielnicki | ![]() |
![]() |
|||
PB-051 | Ir-CPI, a FXIa/FXIIa Inhibitor, Provides an Effective and Safe Thromboprotection During Extracorporeal Circulation Associated with Open-heart Surgery | Valérie Pireaux | ![]() |
![]() |
|||
PB-052 | Evaluation of Hemostasia in the Search of New Anticoagulants of Natural Products: Mikania Laevigata | Luci Dusse | ![]() |
![]() |
|||
PB-053 | Antithrombotic Effect of the Chimeric (Recombinant Form) of Bauhinia bauhinioides Kallikrein Inhibitor and its Structurally Related Peptide in the Experimental Arterial Thrombosis Model in Mice | Maria Luiza Vilela Oliva | ![]() |
![]() |
|||
PB-054 | FVII: a human pluripotent stem cell derived hepatocyte model with potential therapeutic applications | Maria Eugenia Chollet Dugarte | ![]() |
![]() |
|||
PB-056 | A way to make rodent FXIa accessible to human FXIa small molecule inhibitors | Mayken Visser | ![]() |
![]() |
|||
PB-057 | Thrombin Generation in Trauma Patient Plasma | Saulius Butenas | ![]() |
![]() |
|||
PB-061 | Supraphysiological intrahepatic bile acid concentrations induce tissue factor activity in hepatocytes | Axel Schlagenhauf | ![]() |
![]() |
|||
PB-064 | Apixaban suppresses the release of TF-positive microvesicles and restrains cancer cell proliferation through directly inhibiting TF-fVIIa activity | Sophie Featherby | ![]() |
![]() |
|||
PB-065 | Excess tissue factor is preferentially cleared from endothelial cells through microvesicle release and then, by caveolae-mediated internalisation, through a mechanism requiring fVIIa | Yahya Madkhali | ![]() |
![]() |
|||
PB-066 | The ratio of factor VIIa:tissue factor content within microvesicles determines the differential influence on endothelial cells | Yahya Madkhali | ![]() |
![]() |
|||
PB-067 | The cellular location of tissue factor is constrained by MAGI-1 and is releasd by PAR2 activation | Mohammad Mohammad | ![]() |
![]() |
|||
PB-068 | Long term exposure to tissue factor induce cell proliferation by lowering PTEN protein levels | Mohammad Mohammad | ![]() |
![]() |
|||
PB-069 | Ex-vivo Trial of BT200 in Healthy Volunteers after Receiving Desmopressin or Endotoxin | Katarina D. Kovacevic | ![]() |
![]() |
|||
PB-070 | Evaluation of Platelet-dependent VWF Activity on an Heterogeneous Group of von Willebrand Disease Patients Using Four Different Methods: Two VWF:GPIbM and Two VWF:RCo Assays | Luciano Baronciani | ![]() |
![]() |
|||
PB-072 | Identification of murine Macrophage Galactose Lectin 2 as a novel VWF clearance receptor sheds light on differential clearance pathways for hyposialylated VWF variants | Soracha Ward | ![]() |
![]() |
|||
PB-073 | VWF production and secretion, and endothelial cell characteristics in healthy ECFCs; Generating a valid ex vivo model for VWD | Suzan de Boer | ![]() |
![]() |
|||
PB-076 | Digestion of ADAMTS13 by plasmin in human plasma increase the risk of thrombotic thrombocytopenic purpura | Yongchol Shin | ![]() |
![]() |
|||
PB-077 | Cleavage of von Willebrand factor multimers and fibrinogen in human plasma by Plasmin: Effects on hemostasis response | Kenshi Togashi | ![]() |
![]() |
|||
PB-082 | Clinical Audit of Prescriptions for Platelet Therapy Using Computerized Physician Order Entry (CPOE | Bushra Moiz | ![]() |
![]() |
|||
PB-085 | Circulating Intranuclear Proteins May Play a Role in Development of Coagulopathy Following Remission Induction Chemotherapy in Individuals with Acute Leukemia | Kayo Harada | ![]() |
![]() |
|||
PB-086 | Human Platelets Strongly Interact with Glioblastoma (GBM) Cells: Development of a RNAi-transfected Platelet Strategy for Treatment of Relapsing Glioblastoma | Loredana Bury | ![]() |
![]() |
|||
PB-087 | Global Distribution of CYP2C19 Genetic Polymorphisms Affecting Safety or Efficacy of Cardiovascular Medications | Mohitosh Biswas | ![]() |
![]() |
|||
PB-088 | DIGEVAR, a novel software for user-friendly analysis of high-throughput sequencing gene variants in Inherited Platelet Disorders | Jose Rivera | ![]() |
![]() |
|||
PB-089 | Identification of a shared transcriptomic signature between Sickle Cell Disease and Acute Myocardial Infarction patients | Bidossessi Wilfried Hounkpe | ![]() |
![]() |
|||
PB-090 | A single-cell survey reveals a subpopulation of mesenchymal stem cell enriched with coagulation function | Yuchen Gao | ![]() |
![]() |
|||
PB-091 | Analysis of antiproliferative effect of ankaferd blood stopper over caco-2 cancer cells via untargeted proteomics approach | Ibrahim Celallettin Haznedaroglu | ![]() |
![]() |
|||
PB-094 | Transcriptomics analysis of Melanoma Tumors treated with Amblyomin-X, a Kunitz-type FXa inhibitor, searches for pathways and drug targets | Flavio Lichtenstein | ![]() |
![]() |
|||
PB-096 | Spatial Thrombin Generation in Platelet-rich Plasma: Sensitivity to the Alterations of Blood Coagulation and Platelet Function | Anna Balandina | ![]() |
![]() |
|||
PB-097 | The Influence of FXII Deficiency on aPTT in Critically Ill Patients: A Common and Underestimated Problem | Mirjam Bachler | ![]() |
![]() |
|||
PB-098 | Reversal of the Thrombin Generation Inhibitory Effect of Apixaban, Betrixaban, Edoxaban and Rivaroxaban by Andexanet Alpha may be Associated with Increased Thrombogenesis | Fakiha Siddiqui | ![]() |
![]() |
|||
PB-099 | Evaluation of Lupus Anticoagulant Interference in a Chromogenic Factor IX Kit for Determination of Factor IX Activity | Pia Bryngelhed | ![]() |
![]() |
|||
PB-101 | Analytical Validation of Atellica COAG 360 System | Renata Zadro | ![]() |
![]() |
|||
PB-105 | Bringing Thrombin Generation into the Diagnostic Setting: Standardisation and Establishment of Normal Reference Intervals for a Commercial Thrombin Generation System | Sarah Just | ![]() |
![]() |
|||
PB-106 | Comparison of Paired Placental and Venous Neonatal Blood Samples for Coagulation Assay | Erica Scalambrino | ![]() |
![]() |
|||
PB-108 | Analytical Performance of the Free Protein S Assay on the Cobas t 711 Analyser | Steve Kitchen | ![]() |
![]() |
|||
PB-110 | A Novel, Point-of-Care (POC), Hand-held Meter & Strip, Viscoelastic Coagulation Diagnostic Platform for Thromboelastography (TEG) Measurement | Abhishek Ramkumar | ![]() |
![]() |
|||
PB-112 | Comparative Study between Thromboelastography and Conventional Coagulation Tests in Ischemic Cerebral Vascular Disease | Bin Yan | ![]() |
![]() |
|||
PB-115 | Comparison of Thrombin Generation Measured with Calibrated Automated Thrombography versus ST Genesia in Patients with Chronic Liver Disease | Lara N. Roberts | ![]() |
![]() |
|||
PB-116 | Analytical Performance of the Lupus Screen and Lupus Confirm Assays on the Cobas t 711 Analyser | Gergely Rozsnyai | ![]() |
![]() |
|||
PB-118 | Analytical Performance of the Factor X Assay on the cobas t 711 Analyser | Steve Kitchen | ![]() |
![]() |
|||
PB-121 | Integration of routine coagulation tests on a total laboratory automation (TLA) platform in an academic laboratory in South Africa | Susan Louw | ![]() |
![]() |
|||
PB-122 | Evaluation of the performance characteristics of a commercial lyophilized normal pool plasma for utilization in the routine coagulation laboratory | Susan Louw | ![]() |
![]() |
|||
PB-125 | Effect of dabigatran in the very elderly on thrombinography and fibrinography parameters as assessed with the Thrombodynamics® system | Geoffrey Foulon | ![]() |
![]() |
|||
PB-126 | A method to quantify alpha- and beta-antithrombin in plasma | Helen Atkinson | ![]() |
![]() |
|||
PB-127 | Analytical measuring range of exogenous coagulation factors assays with a new extraction thromboplastin | Audrey Carlo | ![]() |
![]() |
|||
PB-128 | Comparison of two thromboplastin reagents for exogenous coagulation factor quantitative determination | Audrey Carlo | ![]() |
![]() |
|||
PB-129 | Reference Range of Platelet Function Analyzer-100 Closure Time (CT) in Thai Adolescent | Narin Khongjaroensakun | ![]() |
![]() |
|||
PB-130 | Exclusion of heparin-induced thrombocytopenia by a rapid lateral-flow immunoassay. Comparison to an immunoturbidimetric assay: Preliminary results | Marina Lopez | ![]() |
![]() |
|||
PB-131 | Evaluation of coagulation profile in patients with adrenal incidentaloma: a two-center observational study | Elena Campello | ![]() |
![]() |
|||
PB-132 | Establishment of a Healthy Donor Reference Range for the T-TAS 01 PL Chip | Jeffrey Dahlen | ![]() |
![]() |
|||
PB-133 | Analytical Performance Characteristics of the T-TAS 01 PL Chip Assay | Jeffrey Dahlen | ![]() |
![]() |
|||
PB-134 | Estimation of the influence of HBB mutation site for the screening ability of calculated RBC indices in ß-thalassemia minor | Soyoung Shin | ![]() |
![]() |
|||
PB-136 | Identifying reasons of excessive coagulation testing in medically ill patients - a sneak peek | Sidra Asad Ali | ![]() |
![]() |
|||
PB-137 | Thromboelastography parameters in normal pregnancies | Elvira Grandone | ![]() |
![]() |
|||
PB-138 | Converting the Distinct Heparins Sourced from Bovine or Porcine Mucosa into a Single Anticoagulant Drug | Stephan-Nicollas M. C. G. de Oliveira | ![]() |
![]() |
|||
PB-139 | Ongoing improvements in laboratory performance of coagulation factors VIII and IX: Recent experience from the RCPAQAP | Emmanuel Favaloro | ![]() |
![]() |
|||
PB-140 | Are Global Coagulation Assays Better Measures of the Intensity of Anticoagulation in Patients with Antiphospholipid Syndrome? | Wan Hui Wong | ![]() |
![]() |
|||
PB-142 | Pronounced alterations of thrombin generation profiles are found in whole blood compared to plasma of liver disease patients | Jun Wan | ![]() |
![]() |
|||
PB-147 | Effects of hemolysis on prothrombin time (PT) and activated partial thromboplastin time (APTT) clot waveform analysis (CWA) | Yu Ling Clarice Lee | ![]() |
![]() |
|||
PB-148 | Antithrombin - prothrombin balance in cirrhosis-associated hypercoagulability | Aurelien Lebreton | ![]() |
![]() |
|||
PB-149 | Evaluation of a new high-throughput haemostasis analyser using coagulation, amidolytic, immuno-turbidometric and light transmission aggregometry assays | Ian Mackie | ![]() |
![]() |
|||
PB-151 | The new QXpert analyser is suitable for routine use in high volume haemostasis laboratories | Anita Woolley | ![]() |
![]() |
|||
PB-156 | A practical method for reducing the interference due to lipaemia in coagulation tests | Ian Mackie | ![]() |
![]() |
|||
PB-157 | External Quality Assessment Scheme for Haemostasis Laboratories in India - Challenges and Opportunities | Alok Srivastava | ![]() |
![]() |
|||
PB-158 | Thrombin generation measurement using the automated ST Genesia Thrombin Generation System in Healthy Adults and Some Adult Patients | Sara Calzavarini | ![]() |
![]() |
|||
PB-161 | Responsiveness of the Activated Partial Thromboplastin Time (APTT) and Dilute Thrombin Time (dTT) to Argatroban: Resuls of a in vitro Study | Erica Scalambrino | ![]() |
![]() |
|||
PB-162 | Mechanisms of Paradoxical Prolongation of Clot Lysis Time by a Direct Thrombin Inhibitor Melagatran: Comparison with a Direct Factor Xa Inhibitor Edoxaban | Yoshiyuki Morishima | ![]() |
![]() |
|||
PB-163 | Heterogeneous Effect of Direct Oral Anticoagulants on Lupus Anticoagulant Assays | Tomas L. Lindahl | ![]() |
![]() |
|||
PB-165 | High Variability in Rivaroxaban and Apixaban Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessed with Thrombin Generation in Patients over 80 Years | Geoffrey Foulon | ![]() |
![]() |
|||
PB-166 | A Novel, Point-of-Care (POC), Hand-held Meter & Strip, Viscoelastic Coagulation Diagnostic Platform for Anticoagulation Therapy Monitoring | Abhishek Ramkumar | ![]() |
![]() |
|||
PB-167 | Neutralising Rivaroxaban Induced Interference in Laboratory Testing for Lupus Anticoagulant (LA): A Comparative Study Using DOAC Stop and Andexanet Alfa | Emmanuel Favaloro | ![]() |
![]() |
|||
PB-169 | Coagulation Function Tests to Measure Direct Oral Anticoagulant (DOAC) Levels: Comparison of Routine and DOAC-specific Tests in the PAUSE Study | James Douketis | ![]() |
![]() |
|||
PB-172 | Correlation of TEG6S with Rivaroxaban level: An Advancement in Point-of-Care Testing | Matthew Neal | ![]() |
![]() |
|||
PB-174 | Evaluation of anti-factor Xa assays for monitoring indirect Xa inhibitors using external quality data | Piet Meijer | ![]() |
![]() |
|||
PB-176 | Evaluation of single-site and multisite precision of apixaban assay | Audrey Carlo | ![]() |
![]() |
|||
PB-178 | DOAC filter efficacy and interest in patients undergoing LA testing | Audrey Carlo | ![]() |
![]() |
|||
PB-180 | Characterization by 5 Different Methods of 16 Structural Variants in SERPINC1 Causing Antithrombin Deficiency | Javier Corral | ![]() |
![]() |
|||
PB-181 | Activated Charcoal Is an Effective in vitro Removal Agent of Dabigatran and Rivaroxaban in Plasma of Patients Who Need Lupus Anticoagulant Testing | Ivana Celap | ![]() |
![]() |
|||
PB-182 | Activated Charcoal for Lupus Anticoagulant Diagnosis in Patients Treated with Direct Oral AntiCoagulants: Results of a Multicenter Study | Virginie Siguret | ![]() |
![]() |
|||
PB-184 | Use of a Novel Assay to Measure Anti-factor Xa Direct Oral Anticoagulant Levels in the Plasma Samples from the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study | Luca Di Giuseppantonio | ![]() |
![]() |
|||
PB-186 | Assessment of an Adsorbent Product to Neutralise the Effect of DOACs on Coagulation Testing | Joanne Clifford | ![]() |
![]() |
|||
PB-188 | Mixing Study to Establish the Diagnosis of Type II Antithrombin Deficiency: A Case Report | Mihir Bhatt | ![]() |
![]() |
|||
PB-189 | Improved Correlation between DOAC Concentrations and Clotting Test Results using the Correction Ratio (before/after DOAC Stop) | Thomas Exner | ![]() |
![]() |
|||
PB-190 | Lack of agreement between different anti-Xa assays to measure low molecular weight heparin (LMWH); results of a UK NEQAS Blood Coagulation study | Ian Jennings | ![]() |
![]() |
|||
PB-192 | Chronometric vs structural hypercoagulability | Carmen Delianu | ![]() |
![]() |
|||
PB-193 | A factor Xa inhibitor antidote (andexanet alfa) is capable of neutralizing the anticoagulant effects of unfractionated heparin of bovine, ovine and porcine origin in a comparable manner as protamine sulfate | Fakiha Siddiqui | ![]() |
![]() |
|||
PB-194 | The (Fab)ulous destiny of idarucizumab: highlighting the interference with urine protein immunofixation | Nicolas Gendron | ![]() |
![]() |
|||
PB-195 | Measurement of Anti-FIIa activity of Bivalirudin in Plasma with Clotting and Chromogenic Assays | Claire Dunois | ![]() |
![]() |
|||
PB-196 | Neutralization of Heparin Interferences in DOACs´ Measurement with Anti-Xa Chromogenic Assays | Claire Dunois | ![]() |
![]() |
|||
PB-197 | Bio-assay for the Measurement of Anti-FXa Activity of Edoxaban and its Metabolites in Plasma | Claire Dunois | ![]() |
![]() |
|||
PB-198 | Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban Does Not Fully Reflect their Biologic Spectrum | Fakiha Siddiqui | ![]() |
![]() |
|||
PB-200 | Prothrombinase Induced Clotting Time Is More Sensitive then aPTT and PT and Can Be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma | Fakiha Siddiqui | ![]() |
![]() |
|||
PB-202 | Study of the Serum Immunoglobulin and Cell-mediated Immunity in Patients with Congenital Severe Hemophilia | Mehran Karimi | ![]() |
![]() |
|||
PB-203 | Biochemical Evidence and Functional Effects of Molecular Aggregation of Marketed Recombinant FVIII Products | Raimondo De Cristofaro | ![]() |
![]() |
|||
PB-204 | Quality Control in Hemophilia: Perfomance Evaluation of Eighteen Laboratories in Argentina | Pablo Martinez | ![]() |
![]() |
|||
PB-207 | High Prevalence of Recurrent F8 Genotypes in the First Series of Argentine Patients with Mild Hemophilia A | Liliana Rossetti | ![]() |
![]() |
|||
PB-211 | Factor VIII pharmacokinetics associate with VWF clearance, VWF-FVIII binding activity, and variants in the CLEC4M gene in an adult hemophilia A population | Kenichi Ogiwara | ![]() |
![]() |
|||
PB-213 | Favourable recombinant factor IX pharmacokinetics outcomes in severe hemophilia B patients with FIX activation site mutations | Alessio Branchini | ![]() |
![]() |
|||
PB-214 | Evaluation of single-site and multisite precision of factor IX measurement | Claire Martin | ![]() |
![]() |
|||
PB-215 | Evaluation of single-site and multisite precision of factor VIII measurement | Claire Martin | ![]() |
![]() |
|||
PB-218 | An Inv22-like F8 Inverted Disruption in Severe Hemophilia A Brothers Possibly Occurring from Template Switching between Sister Chromatids | Shogo Tamura | ![]() |
![]() |
|||
PB-219 | Dosage of factor IX in persons with Hemophilia B treated with recombinant FIX linked to an IgG Fc domain: comparison of 3 methods in a French hospital | Valérie Proulle | ![]() |
![]() |
|||
PB-222 | Bone Disease in Hemophilia: The Role of Different Bone Cells | Stefano Lancellotti | ![]() |
![]() |
|||
PB-223 | Co-administration of FVIII with IVIG: Effect on Immune Response to FVIII in Hemophilia A Mice | Gonzalo Hortelano | ![]() |
![]() |
|||
PB-224 | Synergistic effect of the bypassing agents and sequence identical analogue of emicizumab on secondary hemostasis in in vitro model of hemophilia A | Jovan Antovic | ![]() |
![]() |
|||
PB-225 | Severe haemophilia A caused by an unbalanced chromosomal rearrangement identified using nanopore sequencing | Claude Négrier | ![]() |
![]() |
|||
PB-226 | Rotem analysis shows variable clot formation in subjects with intron 22 inversion- a possible explanation for the variable phenotype | Colleen Hamid | ![]() |
![]() |
|||
PB-227 | Low plasma level of OPG in hemophilia A boys | Zhenping Chen | ![]() |
![]() |
|||
PB-230 | Improvement the APTT-based Mixing Test for Anti Factor VIII | Emanuel Sueldo | ![]() |
![]() |
|||
PB-231 | Validation of an Automate Chromogenic Assay Factor VIII:C | Emanuel Sueldo | ![]() |
![]() |
|||
PB-232 | Thrombin Generation in Subjects with Hemophilia A According to the ABO Blood Group | Fernanda Martins Lott Fonseca | ![]() |
![]() |
|||
PB-234 | Improved Hemostasis and Joint Health over Time in a Subset of Patients who Did Not Reach Optimal Hemostatic Control in the First Year of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Therapy | K. John Pasi | ![]() |
![]() |
|||
PB-236 | Immune Tolerance Induction Using Low-dose Fc Fusion Recombinant Factor VIII on Emicizumab in Hemophilia A Patients with Inhibitors, Tokyo Protocol | Azusa Nagao | ![]() |
![]() |
|||
PB-237 | Comparison of Pharmacokinetic Parameters of Two Different Extended Half-life factor VIII Concentrates in Hemophilia A (HA) Patients | Jerome Teitel | ![]() |
![]() |
|||
PB-238 | Successful Haemostatic Response during the Treatment of Bleeding Episodes and Effective Prophylaxis with Turoctocog Alfa in Previously Treated Patients from China with Severe Haemophilia A (Guardian 7) | Renchi Yang | ![]() |
![]() |
|||
PB-239 | N8-GP Treatment Sustains Low Bleeding Rates in Patients with Haemophilia A | Meera Chitlur | ![]() |
![]() |
|||
PB-240 | Quality of Life of Hemophilia Patients with Inhibitors - Opportunities for Improvement | Howard Levy | ![]() |
![]() |
|||
PB-241 | Daratumumab in Combination with Rituximab and Immune Tolerance Induction Can Rapidly Eradicate High-titer Factor VIII Inhibitor in a Patient with Hemophilia A | Chatphatai Moonla | ![]() |
![]() |
|||
PB-242 | Long-term Safety and Efficacy of Nonacog Beta Pegol in Previously Treated Children with Haemophilia B, Treated for at Least 5 Years | Manuel Carcao | ![]() |
![]() |
|||
PB-247 | Public Health Policy Analysis of Clotting Factor Concentrate Procurement Policy in Canada | Zachary Liederman | ![]() |
![]() |
|||
PB-248 | D-dimer Levels in Haemophilic Patients | Brigitte Tardy-Poncet | ![]() |
![]() |
|||
PB-249 | Relationship between Serum Cartilage Turnover Biomarkers and Hemophilic Arthropathy Severity in Adult Patients with Severe Hemophilia A in China | Xueyan Sun | ![]() |
![]() |
|||
PB-251 | Perioperative Management of Eight Patients with Congenital Hemophilia A who Underwent Spinal Surgery in a Single Facility | Yushi Chikasawa | ![]() |
![]() |
|||
PB-254 | The WFH World Bleeding Disorders Registry - One Year Later | Barbara Konkle | ![]() |
![]() |
|||
PB-255 | Pharmacokinetic analysis in Hemophilia patients using WAPPS-Hemo: the experience of a single center | Alessandra Nunes Loureiro Prezotti | ![]() |
![]() |
|||
PB-256 | Hereditary Protein S Deficiency in a Family with Hemophilia B- Case Report | Alessandra Nunes Prezotti | ![]() |
![]() |
|||
PB-259 | The gene mutation and factor activity of hemophilia carriers in China | Qun Hu | ![]() |
![]() |
|||
PB-260 | Expected timing of initial exposure to factor VIII treatment in non-replacement therapies in hemophilia A | Fabienne Roelfien Kloosterman | ![]() |
![]() |
|||
PB-261 | Cross-sectional comparative study of pharmacokinetics and efficacy after the switch between Kogenate and Kovaltry guided by WAPPS-Hemo | Santiago Bonanad | ![]() |
![]() |
|||
PB-264 | Web-based Application for the Population Pharmacokinetic Service (WAPPS)´s Impact on Dosage Selection: A Single Pediatric Centre Experience, Retrospective Review | Celia Kwan | ![]() |
![]() |
|||
PB-265 | Unexpected diagnostic of aggressive stage IV non Hodgkin Lymphoma in a severe hemophilia A patient | Melen Brinza | ![]() |
![]() |
|||
PB-267 | Effects of Preventive Physiotherapy on Joint Function and Health-related Quality of Life in Pediatric Patients with Severe Bleeding Disorders | Ralf Knoefler | ![]() |
![]() |
|||
PB-268 | Extended half-life recombinant factor IXFc is effective in preventing bleeding after major and minor surgery in severe Factor IX deficiency | Kate Johnston | ![]() |
![]() |
|||
PB-270 | Circumcision and Complications in Patients with Hemophilia and the Other Bleeding Disorders in Southern Part of Turkey: Cukurova Experience | Ali Bulent Antmen | ![]() |
![]() |
|||
PB-271 | Intracranial Hemorrhage and Management in Hereditary Bleeding Disorders: The Experience of Cukurova | Hatice Ilgen Sasmaz | ![]() |
![]() |
|||
PB-272 | OLD HEMOPHILIA PATIENTS HAVE PROBLEMS OTHER THAN BLEEDING: LIKE CANCER | Fahri Sahin | ![]() |
![]() |
|||
PB-287 | Performance of a Clinical Risk Prediction Model for Inhibitor Formation in Severe Hemophilia A | Shermarke Hassan | ![]() |
![]() |
|||
PB-290 | Prevention of Bleeding in Haemophilia A by Prophylactic Treatment with Simoctocog Alfa and 2 Plasma-derived Factor VIII Concentrates: A Snapshot Analysis of a Prospective, Non-interventional Study to Evaluate Real-life Prophylactic Treatment Schedules - N | Carmen Escuriola-Ettingshausen | ![]() |
![]() |
|||
PB-291 | New Inhibitors in the Ageing Hemophilia Population (NIAP) Study: An International, Retrospective, Observational, Cohort Study of New Inhibitors in People with Hemophilia Aged 40 Years and Older | Jan Astermark | ![]() |
![]() |
|||
PB-292 | Prophylaxis with Emicizumab in Children and Adults with Hemophilia A and Inhibitors: Preliminary Data on 7 Patients of a Portuguese Hemophilia Center | Cristina Catarino | ![]() |
![]() |
|||
PB-293 | Circumcision in Haemophilia in the Setting of Low Factor Availabilty: Experience from Gombe, Nigeria | Saleh Yuguda | ![]() |
![]() |
|||
PB-306 | Systemically administered LV-FVIII and LV-FIX confers normal level of clotting factor expression with no evidence of oncogenesis in non-human primates | Rob Peters | ![]() |
![]() |
|||
PB-307 | FVIII Expression by its Native Promoter Sustains Long-term Correction Avoiding Immune Response in Hemophilic Mice | Antonia Follenzi | ![]() |
![]() |
|||
PB-310 | Correction of Canine Hemophilia A via Intraosseous Delivery of a Platelet-specific Factor VIII-lentiviral Vector | Chong Li | ![]() |
![]() |
|||
PB-316 | Development of Single Domain Antibodies Targeting Protease Nexin-1 as a Strategy for Hemophilia Treatment | Charlotte Kawecki | ![]() |
![]() |
|||
PB-317 | A Comparison of Clot Waveform Analysis and Thrombin Generation Assay in the Laboratory Assessment of Haemostatic Function in a Patient on Emicizumab | Joyce Ching Mei Lam | ![]() |
![]() |
|||
PB-318 | Treatment of Hemophilia A Using Factor VIII Messenger RNA Encapsulated in Lipid Nanoparticle | Chun-Yu Chen | ![]() |
![]() |
|||
PB-319 | Management of surgery in hemophilia A patients with inhibitors during emicizumab prophylaxis | Christine Biron-Andreani | ![]() |
![]() |
|||
PB-320 | Next Generation Factor VIIa with Enhanced Half-Life | Mattia Ferrarese | ![]() |
![]() |
|||
PB-321 | Rescue of multiple Haemophilia A-causing mutations by a single ExSpeU1: the importance of the genomic context | Dario Balestra | ![]() |
![]() |
|||
PB-326 | The Role of Platelet Mitochondrial Function for Platelet Mediated Aß40 Aggregation | Lili Donner | ![]() |
![]() |
|||
PB-328 | Platelet-derived calpain mediates protease-activated receptor 1-dependent vascular inflammation in Diabetes | Voahanginirina Randriamboavonjy | ![]() |
![]() |
|||
PB-331 | Disturbed Blood Flow-induced Platelet Transmigration Modulates Vascular Inflammation | Chaojun Tang | ![]() |
![]() |
|||
PB-335 | Statins Effects on Endothelium Dependent Relaxation of Rat Resistance Arteries Affected by Homocysteine Exposure | Loredana Liliana Hurjui | ![]() |
![]() |
|||
PB-336 | Development of an Algorithm to Predict Mortality in Patients with Sepsis and Coagulopathy | Matthew Rondina | ![]() |
![]() |
|||
PB-337 | The Anti-inflammatory effect of e-viniferin by Specifically Targeting fMLP Receptor in Human Neutrophils | Hsiang-Ruei Liao | ![]() |
![]() |
|||
PB-339 | Aspirin Inhibits Intravascular Coagulation during Sepsis in Mice | Agostina Carestia | ![]() |
![]() |
|||
PB-341 | Standardisation of Protocols for the Diagnosis of Neonatal Sepsis by Molecular Methods | Anjali Kelkar | ![]() |
![]() |
|||
PB-342 | PECAM-1 protects sepsis-induced DIC by dampening inflammatory response and restoring vascular barrier | Heng Mei | ![]() |
![]() |
|||
PB-345 | Role of the thrombotic markers, NETs and thrombin generation test, in the diagnosis of prosthetic infection | Julia Oto | ![]() |
![]() |
|||
PB-347 | Plasma Thrombogenic Potential in Patients with Granulomatosis with Polyngiitis (GPA) | Jacek Musial | ![]() |
![]() |
|||
PB-348 | CENTD-centre of Excellence in New Target Discovery: The Use of Animal Venoms to Identify Molecular Targets and Signaling Pathways Involved in Inflammatory Related Diseases | Ana Marisa Chudzinski-Tavassi | ![]() |
![]() |
|||
PB-349 | Neutrophil-to-Lymphocyte ratio is associated with poor prognosis after endovascular thrombectomy in stroke patients | Manuel Navarro-Oviedo | ![]() |
![]() |
|||
PB-351 | Natural IgM antibodies reduce plasmatic coagulation | Christoph J Binder | ![]() |
![]() |
|||
PB-352 | Plasma levels of microRNAs and future risk of incident venous thromboembolism | Vânia Maris Morelli | ![]() |
![]() |
|||
PB-354 | Coxsackievirus B3 decreased angiogenic activity of endothelial colony forming cells through TLR3 activation | Paula Romina Zubiry | ![]() |
![]() |
|||
PB-355 | Association of Platelet Response to Cilostazol with Clinical Outcome and CYP Genotype in Patients with Cerebral Infarction | Yuichi Ikeda | ![]() |
![]() |
|||
PB-356 | Investigation of the in vitro Effect of Aspirin and Tirofiban in Children Compared to adults | Xavier Busuttil-Crellin | ![]() |
![]() |
|||
PB-357 | Value of High Platelet Reactivity in Predicting Major Adverse Cardiovascular Events in Hypertension Patients with Coronary Atherosclerotic Heart Disease after PCI | Qinkun Fan | ![]() |
![]() |
|||
PB-358 | Effect of cilostazol in combination with clopidogrel on platelet function in patients with ischemic stroke at high risk of recurrence | Masako Yamazaki | ![]() |
![]() |
|||
PB-359 | Evaluation of the Newly-developed ADP induced platelet aggregation level (APAL) system in aggregometer on automated coagulation analyzer | Tasuku Sakayori | ![]() |
![]() |
|||
PB-360 | ASPIRIN RESPONSIVENESS IN ESSENTIAL THROMBOCYTHEMIA | Marco Cattaneo | ![]() |
![]() |
|||
PB-361 | Clinical predictiveness of six major platelet function tests used to assess aspirin response in patients with stable coronary artery disease - 10-year follow-up | Marie Lordkipanidzé | ![]() |
![]() |
|||
PB-362 | Management of antiplatelet therapy in the pacemaker implant. Retrospective study in our intensive care unit | Pablo Romero Garcia | ![]() |
![]() |
|||
PB-363 | Efficacy and Adverse Reactions of Hydroxyurea and Interferon-alpha in a Cohort of Chinese Patients with Essential Thrombocythemia | Xinyue Dai | ![]() |
![]() |
|||
PB-364 | Development of Novel Drug-Eluting Stents for Acute Myocardial Infarction to Prevent Stent Thrombosis | Myung Ho Jeong | ![]() |
![]() |
|||
PB-365 | Reversing oral antiplatelet agents with platelet transfusion: a review | Paul Kruger | ![]() |
![]() |
|||
PB-366 | Reversal of the anti-aggregant effect of ticagrelor using untreated platelets | Paul Kruger | ![]() |
![]() |
|||
PB-368 | Aspirin and Clopidogrel Resistance in Patients with Ischemic Vascular Disease in Indonesian Hospital | Vivien Puspitasari | ![]() |
![]() |
|||
PB-369 | Prospective Evaluation of the HEP Score and 4Ts Score in Patients with Suspected Heparin-induced Thrombocytopenia from China | Sen Li | ![]() |
![]() |
|||
PB-370 | Performance Characteristics of Latex Immunoturbidimetric Assay and Particle Immunofiltration Assay for the Diagnosis of Immune Heparin-induced Thrombocytopenia | Shu-Jie Wang | ![]() |
![]() |
|||
PB-373 | Serological Investigation of Suspected Heparin Induced Thrombocytopenia in China: 69 Hospitals | Qingkun Fan | ![]() |
![]() |
|||
PB-375 | Clinical Outcomes in Patients with Discordant Heparin-Induced Thrombocytopenia Laboratory Testing | Zi Yun Ng | ![]() |
![]() |
|||
PB-377 | Transition from argatroban to vitamin K antagonists in the real life : chromogenic factor X assay alone fails to predict international normalized ratio | Dorothée Faille | ![]() |
![]() |
|||
PB-378 | Fondaparinux in patients with heparin-induced thrombocytopenia and dialysis; a case report, and systematic review of available literature | Matthew Wanat | ![]() |
![]() |
|||
PB-379 | Fibrin monomers to monitor anticoagulation with argatroban in patients with acute heparin induced thrombocytopenia | Dorothée Faille | ![]() |
![]() |
|||
PB-380 | Implementation of electronic 4T score improves platelet factor 4 (PF4) ELISA utilization | Lisa Baumann Kreuziger | ![]() |
![]() |
|||
PB-381 | Autoimmune HlT - Successful Treatment with IvigG and DOAC and Laboratory Testing of ivIgG Therapy in HIPA-test | Karina Althaus | ![]() |
![]() |
|||
PB-382 | Natural History of Heparin-induced Thrombocytopenia (HIT) in Cancer: A Cohort Analysis of Thrombosis and Bleeding Outcomes | Cristhiam Mauricio Rojas Hernandez | ![]() |
![]() |
|||
PB-383 | Abnormal Expression of CD47 on Platelet Surface Participates in the Pathogenesis of ITP | Zeping Zhou | ![]() |
![]() |
|||
PB-384 | Abnormal Expression of APRIL may be Involved in the Pathogenesis of ITP | Zeping Zhou | ![]() |
![]() |
|||
PB-385 | Glycoprotein-Specific Direct Platelet Autoantibody Testing in Immune Thrombocytopenia: A Modern Reassessment | David Kuter | ![]() |
![]() |
|||
PB-386 | Immature Platelet Fraction as a Predicting Factor for Hemorrhage in Immune Thrombocytopenic Purpura | Huu Tuan Nguyen | ![]() |
![]() |
|||
PB-387 | High Dose Dexamethasone vs Prednisolone Therapy in Newly Diagnosed Myanmar Adult Patients with Primary Immune Thrombocytopenia | HtunLwin Nyein | ![]() |
![]() |
|||
PB-389 | Detection and Treatment of Helicobacter pylori in Patients with Immune Thrombocytopenia: An International Survey | Prakash Vishnu | ![]() |
![]() |
|||
PB-390 | The let-7b-5p Contributes to B Cell Activation and Survival in the Pathogenesis of Immune Thrombocytopenia by Targeting ADAM10 | Yang He | ![]() |
![]() |
|||
PB-391 | "Wait and Watch Approach" for ITP in Kabuki Syndrome | Mona Faramawy | ![]() |
![]() |
|||
PB-393 | Levels of Cytokines Secreted by T lymphocyte and the Relationship with Prognosis in Children Immune Thrombocytopenia | Jingyao Ma | ![]() |
![]() |
|||
PB-394 | Efficacy and safety of eltrombopag in the treatment of severe chronic immune thrombocytopenia in children: a single-center observational study | Hao Gu | ![]() |
![]() |
|||
PB-395 | Fibrinogen levels are associated with bleeding in patients with Immune thrombocytopenia | Heng Mei | ![]() |
![]() |
|||
PB-397 | Evaluation of therapeutic response in pediatric immune thrombocytopenic purpura (ITP) patients | Kousar Perveen | ![]() |
![]() |
|||
PB-399 | Baseline Endogenous Thrombopoietin Concentrations and Response to Avatrombopag in Immune Thrombocytopenia | David Kuter | ![]() |
![]() |
|||
PB-401 | A systematic review and meta-analysis of the use of thrombopoietin receptor agonists in patients with primary Immune Thrombocytopenia | Marco Cattaneo | ![]() |
![]() |
|||
PB-402 | Response to treatment of paraneoplastic immune thrombocytopenia (ITP): a systematic review | Marco Cattaneo | ![]() |
![]() |
|||
PB-403 | Mutation Spectrum of ITP by NGS Sequencing | Mankai Ju | ![]() |
![]() |
|||
PB-404 | The effect of laparoscopic splenectomy for chronic ITP patients | Jun He | ![]() |
![]() |
|||
PB-405 | Clinical Profile and Treatment Outcome of ITP In Malaysia: A Single Centre Experience | Tze Shin Leong | ![]() |
![]() |
|||
PB-408 | Clinical patterns and response to treatment of a cohort of immune thrombocytopenia patients in Singapore | Shin Yeu Ong | ![]() |
![]() |
|||
PB-409 | Immune thrombocytopenic purpura management and outcome: A single center study | Munira Borhany | ![]() |
![]() |
|||
PB-411 | Increased platelet size and pre-activation are associated with bleeding in children with chronic but not persistent immune thrombocytopenia | Anastasia A. Ignatova | ![]() |
![]() |
|||
PB-413 | The Efficacy and Safety of Short Course High-dose Dexamethasone as First-line Treatment regimen for Childhood Newly diagnosed Immune Thrombocytopenia | Lingling Fu | ![]() |
![]() |
|||
PB-414 | A 5 year retrospective longitudinal study of assessment and initial treatment of acute ITP in adults | John Hanley | ![]() |
![]() |
|||
PB-415 | The Role of Flow Cytometric Detection of Platelet Associated Immunoglobulins in Immune Thrombocytopenic Purpura Diagnosis | Andra Grigore | ![]() |
![]() |
|||
PB-416 | Comparable Avatrombopag (AVA) Efficacy in Patients with Chronic Immune Thrombocytopenia (c-ITP) Following Failure of Prior Thrombopoietin Receptor Agonist (TPO-RA) Treatment | Michael Vredenburg | ![]() |
![]() |
|||
PB-417 | Avatrombopag (AVA) Dosing Regimen in Chronic Immune Thrombocytopenia (ITP) - A Dose Modeling Study | Michael Vredenburg | ![]() |
![]() |
|||
PB-418 | Lack of Clinically Significant Hepatotoxicity in Patients with Chronic Immune Thrombocytopenia (c-ITP) Treated with the Novel, Oral Thrombopoietin Receptor Agonist Avatrombopag-pooled Safety Analysis of Four Clinical Trials | Michael Vredenburg | ![]() |
![]() |
|||
PB-421 | In vitro Blockage of CD72 Dose Not Influence ITP Patients Lymphocyte Proliferation and Platelet Antibody Secretion | Jianhui Xu | ![]() |
![]() |
|||
PB-422 | Measuring Preplatelet Division: An Imaging Cytometry Approach | Paul Harrison | ![]() |
![]() |
|||
PB-424 | Imaging actin dynamics throughout megakaryocyte ingression membrane system development | Steve Thomas | ![]() |
![]() |
|||
PB-427 | Differential Effects of Ticagrelor with or without Aspirin on Platelet Reactivity and Coagulation Activation | Ludwig Traby | ![]() |
![]() |
|||
PB-429 | Disagregin: a possible new aIIbß3 integrin inhibitor to prevent arterial thrombosis | Tilman M. Hackeng | ![]() |
![]() |
|||
PB-430 | Amplified Antithrombotic Effects of a Novel GPVI Inhibitor ACT017 when Used in Combination with Aspirin and Ticagrelor | Fawaz Alenazy | ![]() |
![]() |
|||
PB-431 | APAC, a dual anticoagulant and antiplatelet, synergistically with acetylsalicylic acid inhibits collagen-induced platelet aggregation | Riitta Lassila | ![]() |
![]() |
|||
PB-435 | The Active Recruitment of Red Blood Cells during Hemostasis and Thrombus Formation | Meike Klier | ![]() |
![]() |
|||
PB-440 | Critical Role of Platelet-Derived VWF in Acute Occlusion of Stenosed Arteries | Katrina J Ashworth | ![]() |
![]() |
|||
PB-442 | The Effect of Fibrinogen in Platelet Function Activity Using Viscoelastic Method among Neurological Disorder Patient | Leni Lismayanti | ![]() |
![]() |
|||
PB-444 | Flow Cytometry Mepacrine Uptake/Release Combined with CD63 Assay in Diagnosis of Patients with Platelet Disorders | Mara Agazzoni | ![]() |
![]() |
|||
PB-445 | A Method for Determining the Density and Architecture of in vitro Thrombi Formed under Flow | Joanne Mitchell | ![]() |
![]() |
|||
PB-448 | Platelet Ageing Causes Changes in Key Metabolic and Structural Proteins | Harriet E. Allan | ![]() |
![]() |
|||
PB-449 | HLA I cell surface expression is a reliable marker to identify young platelets | Arnaud Dupuis | ![]() |
![]() |
|||
PB-451 | The Effect of Thrombin Binding to GPIba on its Binding with von Willebrand Factor | Shinya Goto | ![]() |
![]() |
|||
PB-455 | Cold-stored Platelets: Procoagulant or Apoptotic? | Lacey Johnson | ![]() |
![]() |
|||
PB-456 | Calcium ion chelation preserves platelet function during cold storage | Guoying Zhang | ![]() |
![]() |
|||
PB-457 | Characterization of outside-in aIIbß3 signaling in platelets by Protein Kinase Cd | Preeti Kumari Chaudhary | ![]() |
![]() |
|||
PB-461 | The cell-cycle control pathway Gwl/MASTL-ENSA/ARPP19-PP2A is present and active in human platelets | Elena Kumm | ![]() |
![]() |
|||
PB-465 | Acute Phase Neutrophil Trafficking is Orchestrated by Platelet Serotonin | Maximilian Mauler | ![]() |
![]() |
|||
PB-467 | Extracellular Vesicles secreted by activated CD4+ T cells activate platelets | Maria Albertina Romaniuk | ![]() |
![]() |
|||
PB-475 | Triple Positivity Profile of Antiphospholipid Antibodies (aPL) is Associated with a Greater Amount of Non-criteria Manifestations on Obstetric Antiphospholipid Antibodies Syndrome (OAPS) | Gabriela de Larrañaga | ![]() |
![]() |
|||
PB-476 | Standardization and Reliability of Lupus Anticoagulant Tests: Comparison of Real World and Core Laboratory Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Analysis | Maria Efthymiou | ![]() |
![]() |
|||
PB-477 | Immunothrombosis and the Role of Neutrophil Extracellular Traps (NETs) in the Pathogenesis of Antiphospholipid Syndrome | Nevine Kassim | ![]() |
![]() |
|||
PB-478 | Prevalence and Clinical Significance of Protein C Antibodies and Acquired Activated Protein C Resistance in Systemic Lupus Erythematosus | Maria Efthymiou | ![]() |
![]() |
|||
PB-479 | Systematic Review and Case Series of Patients with Antiphospholipid Syndrome and Myeloproliferative Neoplasm | Zara Sayar | ![]() |
![]() |
|||
PB-480 | Aspirin or Heparin or Both for Improving Pregnancy Outcomes in Women with Persistent Antiphospholipid Antibodies and Recurrent Pregnancy Loss | Eva Nicole Hamulyák | ![]() |
![]() |
|||
PB-481 | High Antiphospholipid Antibody Positivity among Children and Adolescents with Non-Transfusion-Dependent Thalassemia | Nongnuch Sirachainan | ![]() |
![]() |
|||
PB-483 | Citrullinated Histone H3, a Marker of Neutrophil Extracellular Trap Formation, is increased in Patients with persistent Lupus Anticoagulant and a History of Thrombosis | Lena Hell | ![]() |
![]() |
|||
PB-486 | SHE WON´T STOP CLOTTING DESPITE ON ANTICOAGULANTS: A CHALLENGING CASE | Bee Sun Lee | ![]() |
![]() |
|||
PB-487 | Cut-off generation for percent correction of screen by confirm in lupus anticoagulant testing in multiple reagents with a common set of normal donor plasmas | Osamu Kumano | ![]() |
![]() |
|||
PB-488 | The usefulness of paired APTTs by low and high lupus anticoagulant sensitivity for the discrimination in direct oral anticoagulant drug samples | Osamu Kumano | ![]() |
![]() |
|||
PB-489 | Intestinal permeability: an etiological factor in obstetric antiphospholipid syndrome? | Valérie Louise Bernice Isabelle Jansen | ![]() |
![]() |
|||
PB-490 | Successful Treatment with Eculizumab in a Patient with Antiphospholipid Syndrome Presenting with a Thrombotic Storm | Hana Lim | ![]() |
![]() |
|||
PB-493 | High Incidence of Antiphospholipid Antibody Positivity in Newly-Diagnosed Lymphoma Patients and A Proposed APLA Predictive Score | Theera Ruchutrakool | ![]() |
![]() |
|||
PB-494 | Unfavorably altered plasma fibrin clot properties are associated with increased antiphosphatidylserine/prothrombin complex antibodies in patients with antiphospholipid syndrome | Anetta Undas | ![]() |
![]() |
|||
PB-495 | Thrombin generation in normal plasma spiked with total IgG and affinity purified aß2GPI from high risk APS patients | Vittorio Pengo | ![]() |
![]() |
|||
PB-496 | PFA-200 short closure time values induced by triple positive APS patients´ total IgG or anti Beta 2 GPI antibodies | Vittorio Pengo | ![]() |
![]() |
|||
PB-497 | MicroRNAs Identification in Primary Antiphospholipid Syndrome | Camila de Oliveira Vaz | ![]() |
![]() |
|||
PB-498 | Plasmatic Oxidative Stress in Patients with Primary Antiphospholipid Syndrome : a Preliminary Study | Camila de Oliveira Vaz | ![]() |
![]() |
|||
PB-499 | Anti-cardiolipin and anti-ß2glycoprotein I IgA along with the current criteria does not have an added value in screening for clinical symptoms of the antiphospholipid syndrome | Walid Chayoua | ![]() |
![]() |
|||
PB-500 | Gene expression of tissue factor and the risk of thrombosis associated with antiphospholipid syndrome | Camila Vaz | ![]() |
![]() |
|||
PB-501 | Changes in Inflammation and Coagulation Markers in Patients with Thrombotic Primary Antiphospholipid Syndrome Treated with Hydroxychloroquine | Camila Vaz | ![]() |
![]() |
|||
PB-503 | Platelet Hemi-ITAM Signaling Mediated Cancer-associated Venous Thrombosis Inhibited by a Mononclonal Antibody to Podoplanin, SZ-168 | Yiming Zhao | ![]() |
![]() |
|||
PB-505 | Influence of P Selectin Glycoprotein Ligand 1 Polymorphisms on the Development of Thrombosis in Myeloproliferative Neoplasm Patients | Rolandas Gerbutavicius | ![]() |
![]() |
|||
PB-509 | Increase in whole blood clot Stiffness in patients with peritoneal carcinomatosis | Shahsoltan Mirshahi | ![]() |
![]() |
|||
PB-510 | The role of DNA and Histone in the rigidity and viscoelasticity of fibrin clots | Massoud Mirshahi | ![]() |
![]() |
|||
PB-511 | Higher Plasma clot elasticity decreases Clot degradability | Massoud Mirshahi | ![]() |
![]() |
|||
PB-512 | Approach in the study of molecular mechanism in cancer cell implantation on the fibrin network | Massoud Mirshahi | ![]() |
![]() |
|||
PB-515 | Proteomic Investigation of In-Vitro Antineoplastic Effect of Ankaferd Hemostat with 2D Gel Electrophoresis and MALDI-TOF/TOF-MS in HepG2, Caco-2 and HT-29 Cancer Cells | Ibrahim Celalettin Haznedaroglu | ![]() |
![]() |
|||
PB-518 | Cancer-associated Thromboembolism: Antithrombotic Management of Patients Hospitalized at an Academic Medical Center | Larry K. Golightly | ![]() |
![]() |
|||
PB-522 | Differential Gene Expression of Protease-activated Receptors in Solid Tumors Compared to Hematologic Neoplasias | Prakash Vishnu | ![]() |
![]() |
|||
PB-524 | A Real World Comparative Effectiveness Analysis of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin among Medically Ill and Abdominal Surgery Patients in a large US Hospital Database | Zhimin Xiao | ![]() |
![]() |
|||
PB-525 | Effectiveness of an Admission Proforma in Improving Prescription of Thromboprophylaxis in Acutely Ill Medical Patients. Re-valuating Current Performance in University Hospital Limerick (Ireland) a Decade Later | Robert Gilligan | ![]() |
![]() |
|||
PB-526 | Comprehensive VTE Prevention Strategy Including Root Cause Analysis of Hospital-associated Thrombosis Significantly Reduces Potentially Preventable Events: A Single Centre Experience | Lara N. Roberts | ![]() |
![]() |
|||
PB-527 | Benefit-Risk Assessment of 10mg Daily Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness | Gary E. Raskob | ![]() |
![]() |
|||
PB-528 | Extended-Duration Thromboprophylaxis with Rivaroxaban Reduces the Risk of Major and Fatal Vascular Events in Hospitalized Medically Ill Patients | Alex C. Spyropoulos | ![]() |
![]() |
|||
PB-530 | Incidence of Venous Thromboembolic Disease in hospitalized patients at the "Hospital de Clínicas", Montevideo - Uruguay | Cecilia Guillermo | ![]() |
![]() |
|||
PB-531 | Adequacy of Hospital Thromboprophylaxis and Risk Assessment Models in the SWITCO65+ Cohort | Marc Blondon | ![]() |
![]() |
|||
PB-532 | Prophylaxis for Hospital Acquired Venous Thromboembolism: Why VTE Could Not Be Prevented | Anoop Enjeti | ![]() |
![]() |
|||
PB-535 | Risk Factors Associated with the Failure of Post-operative Rivaroxaban Thromboprophylaxis in Total Knee Arthoplasty Patients: A Retrospective Case-control Study | Owais Mian | ![]() |
![]() |
|||
PB-536 | Randomized, Double-blinded Phase II Trial of Weight Adjusted versus Standard Dose Enoxaparin Thromboprophylaxis in Hospitalized Cancer Patients at High Risk for VTE | Jeffrey Zwicker | ![]() |
![]() |
|||
PB-537 | Safety, Tolerability, and Pharmacodynamic Properties of AB002 (E-WE Thrombin), a Recombinant Protein C Activator Thrombin Analog, in Healthy Adult Volunteers | Norah Verbout | ![]() |
![]() |
|||
PB-540 | The anti-factor XIa antibody BAY 1213790 shows dose-dependent antithrombotic efficacy without an increased risk of bleeding on top of antiplatelet treatment in rabbits | Stefan Heitmeier | ![]() |
![]() |
|||
PB-542 | Thrombophilia Caused by Methylene Tetrahydrofolate Reductase (MTHFR) Gene C677T Homozygous Mutation | Tamar Saralidze | ![]() |
![]() |
|||
PB-543 | Racial Differences of Protein S Tokushima and Two Protein C Variants as Genetic Risk Factors for Venous Thromboembolism | Hiroko Tsuda | ![]() |
![]() |
|||
PB-544 | Role of Gender and ABO-blood Group in White Adolescents and Young Adult Patients with First VTE Onset | Ulrike Nowak-Göttl | ![]() |
![]() |
|||
PB-548 | Epidemiological Characteristics of Thromboembolism Related to Oral Contraceptives in Japan: Results of a National Survey | Kazuko Sugiura | ![]() |
![]() |
|||
PB-549 | Genetic and Phenotypic Analyses of Protein S Tokushima and Two Protein C Variants on Healthy Japanese Young Women | Kenta Noguchi | ![]() |
![]() |
|||
PB-551 | The Risk of Venous Thromboembolism Attributed to Recognized Prothrombotic Genotypes | Line H. Evensen | ![]() |
![]() |
|||
PB-555 | Predictors of in-Hospital Mortality in Acute Pulmonary Embolism | Jose Bonorino | ![]() |
![]() |
|||
PB-556 | The Risk of Venous Thrombosis Associated with Elevated Coagulation Factor Levels in the Elderly | Huijie Wang | ![]() |
![]() |
|||
PB-557 | ABO Blood Type is a Predictor of Venous Thromboembolic Events in Patients with Cancer | Simon Mantha | ![]() |
![]() |
|||
PB-559 | Incidence and Risk factors of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in African Americans Compared to Whites in Durham County, North Carolina | Eva Hortas | ![]() |
![]() |
|||
PB-562 | Gender-related differences in venous thromboembolism patients: GARFIELD-VTE | Alexander G. G. Turpie | ![]() |
![]() |
|||
PB-563 | Genetic variants related to venous thromboembolism. Preliminary results of the first study in an argentinian cohort | Federico Aranda | ![]() |
![]() |
|||
PB-565 | Prothrombotic genotypes and mortality risk in individuals with and without venous thromboembolism recruited from the general population | Line H. Evensen | ![]() |
![]() |
|||
PB-566 | Outcomes of Anticoagulation Therapy in Patients by gender - A Single Center Prospective Data | Ana Isabel Casanegra | ![]() |
![]() |
|||
PB-568 | Protein S Deficiency: Prevalence in Latin-America | Cecilia Guillermo | ![]() |
![]() |
|||
PB-569 | The Incidence Rate and Distribution of Venous Thromboembolism by Provoking Status in a Racially Diverse Population | Aaron Mark Wendelboe | ![]() |
![]() |
|||
PB-570 | Underlying co-morbidity explains high levels of protein S in patients with venous thrombosis: results of the MEGA case-control study | Deeksha Khialani | ![]() |
![]() |
|||
PB-571 | Thrombophilia as an underlying cause for Budd Chiari Syndrome | Bushra Moiz | ![]() |
![]() |
|||
PB-576 | A systematic review and meta-analysis of the prevalence of venous thromboembolism in patients with sickle cell disease | Mosaad Almegren | ![]() |
![]() |
|||
PB-581 | Homocysteine screening at the Belfast trust VTE Outpatient Clinic, Northern Ireland | Gary Benson | ![]() |
![]() |
|||
PB-582 | Twenty-two new mutations identified in Czech patients with antithrombin deficiency | Ingrid Hrachovinová | ![]() |
![]() |
|||
PB-586 | Risk Factors Associated with Massive PE | Praveen Hariharan | ![]() |
![]() |
|||
PB-588 | D-dimer, Antithrombin and Thrombin-antithrombin Complex in Deep Vein Thrombosis | Usi Sukorini | ![]() |
![]() |
|||
PB-589 | Molecular Suitability of the Chacma Baboon Model of Acquired Thrombotic Thrombocytopenic Purpura when Evaluating Anti-VWF Agents | Walter Janse Van Rensburg | ![]() |
![]() |
|||
PB-591 | Acquired ADAMTS-13 Deficiency in a Porcine Model of Methicillin-resistant Staphylococcus Aureus (MRSA) Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS) | Trung Nguyen | ![]() |
![]() |
|||
PB-592 | Unsupervised Classification of Multiparametric MRI Correlates with Red Blood Cell, Fibrin and Collagen Content in Murine Model of Venous Thrombosis | Olivia R. Palmer | ![]() |
![]() |
|||
PB-598 | Linking the anti-inflammatory and anticoagulant properties, the natural inhibitor EcTI impairs the physiopathological aspects of thrombosis | Bruno Salu | ![]() |
![]() |
|||
PB-599 | ADAMTS13 Levels Correlate with Renal and Inflammatory Markers in Mice with Type 1 Diabetes Mellitus and Nephropathy | Michelle Teodoro Alves | ![]() |
![]() |
|||
PB-600 | Evaluation of Oral Anticoagulation-associated Intracerebral Hemorrhage Induced by Collagenase VII-S in Rats | Roberto Fonseca | ![]() |
![]() |
|||
PB-603 | Development of a Novel Acute Model to Evaluate the Effect of Pro-fibrinolytic Compounds in Rabbits | Stefan Heitmeier | ![]() |
![]() |
|||
PB-604 | Sickle cell trait accelerates fibrin formation and resistance to fibrinolysis in mice and humans | Anton Ilich | ![]() |
![]() |
|||
PB-608 | Generation of Transgenic Zebrafish with RFP-labeled Young and GFP-labeled Mature Thrombocytes: Analysis of their Lipids | Pudur Jagadeeswaran | ![]() |
![]() |
|||
PB-609 | The Effect of Antithrombin Budapest3 Mutation for the Heparin Binding Affinity of Antithrombin | Krisztina Pénzes-Daku | ![]() |
![]() |
|||
PB-613 | Quantification and Analysis of the Interaction Between TLT-1 and Fibrinogen | Angelia D. Gibson | ![]() |
![]() |
|||
PB-614 | ADAMTS-13: its increase in plasma would have some role in cognitive decline? | Luci Dusse | ![]() |
![]() |
|||
PB-616 | Clinical Implications of Antivenom Failures to Neutralise Coagulotoxicity of African Snake Venoms | Bryan Fry | ![]() |
![]() |
|||
PB-617 | The Clinical Implications of the Differential Coagulopathic Effects of Asian Pit Viper Snake Venoms | Jordan Debono | ![]() |
![]() |
|||
PB-618 | An Overview of Coagulation Disturbances Caused by Australian Elapid Snake Venoms | Christina N. Zdenek | ![]() |
![]() |
|||
PB-619 | Coagulotoxic Activity in Venoms from Coral Snakes of the Americas (genus: Micrurus) | Daniel Dashevsky | ![]() |
![]() |
|||
PB-620 | Pathophysiological Implications of Differential Coagulotoxic Effects of Bitis Viper Snake Venoms | Nicholas Youngman | ![]() |
![]() |
|||
PB-621 | PLXDC2, a Novel Player of the Coagulation Cascade: Results from a Genome Wide Association Study on Plasma FV Levels | Florian Thibord | ![]() |
![]() |
|||
PB-622 | Monitor Lizard (genus: Varanus) Venoms Disrupt the Clotting Ability of Human Fibrinogen | James Dobson | ![]() |
![]() |
|||
PB-623 | Effect of Brazilian Snake Venoms on Hemostasis Evaluated by Thrombin Generation Assay | Luci Dusse | ![]() |
![]() |
|||
PB-624 | The shortened activation peptide of Pseudonaja textilis venom FX confers zymogenicity and resistance to factor VIIIa-IXa activation | Mark Schreuder | ![]() |
![]() |
|||
PB-625 | Variability in Venom Coagulotoxins in Russell´s Vipers (genus: Daboia) Compromise Antivenom Effectiveness | Bianca op den Brouw | ![]() |
![]() |
|||
PB-626 | Pseudonaja textilis factor Va retains structural integrity and cofactor function following proteolysis by activated protein C | Mark Schreuder | ![]() |
![]() |
|||
PB-627 | The Glycan Structure on Factor XIII B Subunit | László Muszbek | ![]() |
![]() |
|||
PB-630 | Polyphosphate-induced Thrombosis is Enhanced in Mice Deficient in Histidine-rich Glycoprotein | Rida Malik | ![]() |
![]() |
|||
PB-631 | Hydrogen-deuterium Exchange (HDX) Mass Spectrometry Highlights Conformational Changes Induced by FXI Activation and Binding of FIX to FXIa | Awital Bar Barroeta | ![]() |
![]() |
|||
PB-632 | FRET-based Assays for the Quantitation of (pro)Thrombin Binding to Factor XI | Awital Bar Barroeta | ![]() |
![]() |
|||
PB-633 | Identification of the Histidine-rich Glycoprotein Domain Responsible for its Inhibition of Factor XIIa | Tammy Truong | ![]() |
![]() |
|||
PB-636 | Role of N-glycosylation on the Secretion, Plasma Levels and Function of Factor XII: Results from Patients with Congenital Disorders of Glycosylation and a Recombinant Model | Maria Eugenia de la Morena-Barrio | ![]() |
![]() |
|||
PB-637 | A novel antithrombotic coating for blood-contacting medical devices | Lucia Musumeci | ![]() |
![]() |
|||
PB-641 | Plasma kallikrein contributes to coagulation by activating factor IX | Mayken Visser | ![]() |
![]() |
|||
PB-642 | Potential Contribution of Kallikrein to the Coagulation System Independent of Factor XII Activation | Juliet Butler | ![]() |
![]() |
|||
PB-644 | Misfolded Proteins Can Differentially Modulate the Contact System | Lewis Hardy | ![]() |
![]() |
|||
PB-646 | Biorelevant Polyanions Modulate the Structure and Stability of Fibrin in a Size-, and Charge-dependent Manner | Krasimir Kolev | ![]() |
![]() |
|||
PB-647 | Structure, Assembly and Dissociation of Plasma Coagulation Factor XIII Complex | Arijit Biswas | ![]() |
![]() |
|||
PB-648 | Impact of Fibrinogen Post-translational Modifications on its Structure and Function | Žofie Sovová | ![]() |
![]() |
|||
PB-649 | Defining the Functional Role and Regulatory Mechanism of Fibrinogen Phosphorylation in Inflammation and Thrombosis | Kingsley R Simpson | ![]() |
![]() |
|||
PB-651 | Interpretation of Maximum Absorbance Data Obtained from Turbidimetry in Plasma Samples | Marlien Pieters | ![]() |
![]() |
|||
PB-654 | Genetic abnormalities of Japanese patient with symptomatic- and asymptomatic-dysfibrinogenemia | Shogo Tamura | ![]() |
![]() |
|||
PB-655 | Intra-assay reproducibility of a precalibrated liquid Clauss fibrinogen assay | Audrey Carlo | ![]() |
![]() |
|||
PB-656 | Fibrin-derived (ß40-66)2 fragment promotes endothelial permeability via the VLDL receptor dependent pathway | Sergiy Yakovlev | ![]() |
![]() |
|||
PB-657 | Acquired factor XIII deficiency in patients under treatment with plasmapheresis: a poorly explored etiology | Fernando Chuliber | ![]() |
![]() |
|||
PB-658 | Phenotype and genotype of FXIII deficiency in two unrelated probands: identification of a novel F13A1 large deletion mediated by complex rearrangement | Qiulan Ding | ![]() |
![]() |
|||
PB-663 | A chemical screen identifies small molecule modulators of fibrinogen production and experimental venous thrombosis | Rui Vilar | ![]() |
![]() |
|||
PB-664 | Both Hemorrhagic and Thrombotic Complications in a patient with Anti-Factor XIII Autoantibody; Characterization of the Antibody | Julien Bovet | ![]() |
![]() |
|||
PB-666 | Improved specificity and performances of a novel photometric automated assay for Factor XIII activity | Claire Dunois | ![]() |
![]() |
|||
PB-667 | Conditions Associated with Low tPA Activity Are Prevalent among Patients with Schizophrenia or Schzoaffective Disorder | Silvia Hoirisch-Clapauch | ![]() |
![]() |
|||
PB-673 | Thrombin-cleaved Osteopontin Enhances B16 Melanoma Growth | John Morser | ![]() |
![]() |
|||
PB-674 | New functions of prelatent antithrombin | Vicente Vicente García | ![]() |
![]() |
|||
PB-677 | Heparanase: a potential new factor concerned to epithelial mesenchymal transition in gastric signet-ring cell adenocarcinoma | Massoud Mirshahi | ![]() |
![]() |
|||
PB-678 | Fibrin deposit on the peritoneal surface serve as a niche for cancer expansion in carcinomatosis patients | Massoud Mirshahi | ![]() |
![]() |
|||
PB-679 | The Evaluation of the Joint Status of Hemophiliac Adults: Single Center Adult Hematology Clinic Experience | Salih Aksu | ![]() |
![]() |
|||
PB-680 | Response to Recombinant FVIIIC Therapy in a Young Haemophilia A Patient with Spiral Fracture of the Left Femur | Wuraola A. Shokunbi | ![]() |
![]() |
|||
PB-682 | Interim Analysis of Effectiveness of Intraarticular Injection of Mononuclear Stem Cells in Hemophilia Patients with Joint Arthropathy: Two Case Reports | Mehran Karimi | ![]() |
![]() |
|||
PB-683 | A Comparison of Haemostatic Response to Recombinant and Plasma-derived Factor VIII Concentrates in Patients with Hemophilia A | Natalia Silina | ![]() |
![]() |
|||
PB-685 | Pharmacokinetic Study of F? in Chinese Boys with Hemophilia | Huang Kun | ![]() |
![]() |
|||
PB-687 | Efficacy of Short-term Individualized Prophylaxis Guided by PK and Joint Evaluation in Chinese Adult Patients with Severe Hemophilia A | Xueyan Sun | ![]() |
![]() |
|||
PB-688 | Use of Lower Dose of Extended Half-life rFVIIISE (Rurioctocog Alfa Pegol) Satisfies Prophylactic Purpose in Hemophilia A | Hugh Kim | ![]() |
![]() |
|||
PB-695 | Clinical and Laboratory evaluation of female carriers of hemophilia | Mariana S. Pastori | ![]() |
![]() |
|||
PB-697 | A United States Multi-Center Analysis of Characteristics Associated with Prescribed Factor Prophylaxis | Duc Tran | ![]() |
![]() |
|||
PB-703 | Final data from the Italian Registry on intracranial haemorrhage in haemophilia patients: EMO.REC Registry (2009-2018) | Ezio Zanon | ![]() |
![]() |
|||
PB-705 | Ideal Body Weight Is Proven Most Reliable to Dose Factor VIII Concentrate in Overweight and Obese Hemophilia A Patients | Iris van Moort | ![]() |
![]() |
|||
PB-706 | Development of a Population Pharmacokinetic Database for Coagulation Factor VIII Octocog Alfa (Advate®) in Taiwan, and Preliminary Assessment of Pharmacokinetic Parameters in Taiwanese Adults | Yeu-Chin Chen | ![]() |
![]() |
|||
PB-707 | High risk of intracranial haemorrhage in adult mild haemophiliac patients: data from the EMO.REC Registry | Ezio Zanon | ![]() |
![]() |
|||
PB-710 | Emicizumab Improves Factor X Activation and Thrombin Generation Similar to Mild Hemophilia in Persons with Hemophilia A and Inhibitors | Marilyn Manco-Johnson | ![]() |
![]() |
|||
PB-711 | The difference of bleeding frequency and hemophilic arthropathy between hemophilia A and hemophilia B patients | Shixuan Wang | ![]() |
![]() |
|||
PB-712 | Incidence, Presentation and Management of Pseudotumors in Hemophilics: A systemic Review | Romana Akbar | ![]() |
![]() |
|||
PB-713 | Impact of low dose prophylaxis vs. on demand treatment in severe hemophilia A patients in Pakistan | Munira Borhany | ![]() |
![]() |
|||
PB-714 | The Relationship between coagulant activity (FVIII levels and Thrombin Generation Assay) and structural evidence of joint disease in patients with mild to moderate haemophilia A | Mike Laffan | ![]() |
![]() |
|||
PB-716 | Clinical validation of population pharmacokinetic model for plasma-derived factor VIII/VWF using WAPPS-Hemo | Santiago Bonanad | ![]() |
![]() |
|||
PB-722 | Real Life Experience in a Portuguese Haemophilia Center After Switching to rFVIII-Fc: the First Results | Cristina Catarino | ![]() |
![]() |
|||
PB-725 | HOSPITALIZATION OF HEMOPHILIA A and B PATIENTS IN BRAZIL - TRENDS FROM 2004 TO 2016 | Ana C. Guersoni | ![]() |
![]() |
|||
PB-726 | The Impact on Australian Haemophilia Nursing Roles after the Introduction of an Interim Agreement of Extended Half Life Products for the Treatment of Haemophilia | Robyn Shoemark | ![]() |
![]() |
|||
PB-727 | ADVANCE-AF: An international, prospective, longitudinal, observational registry study of hemophilia patients with atrial fibrillation | Roger Schutgens | ![]() |
![]() |
|||
PB-731 | Case report: A rare case of concomitant sickle cell disease and haemophilia A with development of a high titre factor VIII inhibitor | Sharon Allen | ![]() |
![]() |
|||
PB-735 | HaemoValue: Development of a Set of Outcomes for Measuring Value in Persons with Haemophilia | Erna Van Balen | ![]() |
![]() |
|||
PB-737 | Exploring the Wider Value of Extended Half-life Products in Haemophilia: A Targeted Literature Review | Anum Shaikh | ![]() |
![]() |
|||
PB-738 | The First Chinese Hemophilia Individualized Prophylaxis Study (CHIPS): Improvement in Health-related Quality of Life (HRQoL) CHO-KLAT Scores in Boys with Severe Hemophilia A in China | YUAN LI | ![]() |
![]() |
|||
PB-739 | Development and Validation of a Population Pharmacokinetic Model for rAHF-FL-PEG (Adynovate): A Report on behalf of the WAPPS-hemo Investigators ad hoc Subgroups | Alfonso Iorio | ![]() |
![]() |
|||
PB-742 | Effect of Lower von Willebrand Factor and Factor XI Levels on Treatment Success of the Levonorgestrel Intrauterine System or Endometrial Ablation in Heavy Menstrual Bleeding - An Explorative Study | Karina Meijer | ![]() |
![]() |
|||
PB-745 | Burden of Rare Bleeding Disorders on Blood Transfusion Services: A Developing Country Perspective | Anila Rashid | ![]() |
![]() |
|||
PB-747 | Prekallikrein and High Molecular Weight Kininogen Deficiency in Oman: A Challenging Diagnosis in Mucosal Bleeding | Hanan Nazir | ![]() |
![]() |
|||
PB-748 | Thrombin Generating Potential, Plasma Clot Formation and Clot Lysis Are Impaired in Patients with Bleeding of Unknown Cause | Stefanie Hofer | ![]() |
![]() |
|||
PB-749 | Demographic and Clinical Data of Afibrinogenemic Patients from the QualyAFIB Study | Claudia Khayat | ![]() |
![]() |
|||
PB-751 | Evaluation of GGCX Missense Mutations Effect on Vitamin K Dependent Proteins Identified in VKCFD1 Patients by a New Assay and in Silico Modeling | Suvoshree Ghosh | ![]() |
![]() |
|||
PB-752 | Archeogenetics of the p.Cys38Arg Variant Associated with FXI Deficiency: A 5,400 Years Old Mutation Identified in Different Southwestern European Countries | Maria Eugenia de la Morena-Barrio | ![]() |
![]() |
|||
PB-753 | Congenital Factor VII Deficiency: Epidemiology, Clinical Characteristics and Management. Experience of the Northern Greece Hemophilia Center | Vasileia Garypidou | ![]() |
![]() |
|||
PB-755 | CONGENITAL FACTOR XI DEFICIENCY, INHIBITOR AND CLOT FORMATION | Erica Scalambrino | ![]() |
![]() |
|||
PB-756 | Genetic profile and clinical management of Rare Bleeding Disorders: Across the province of Sindh, Pakistan | Munira Borhany | ![]() |
![]() |
|||
PB-757 | Genetic characterization of congenital fibrinogen disorders in Polish patients - clinical phenotype and follow-up | Anetta Undas | ![]() |
![]() |
|||
PB-760 | A nightmare in congenital factor XIII deficiency:Inhibitor development with severe bleeding | Serap Karaman | ![]() |
![]() |
|||
PB-762 | A rare case of bleeding in early postpartum due to Factor XII deficiency | Melen Brinza | ![]() |
![]() |
|||
PB-763 | A Heterozygous FGB Variant Causing Hypofibrinogenemia in a Swedish Family | Marcus Fager Ferrari | ![]() |
![]() |
|||
PB-767 | Improving Prevalence Data on Rare Bleeding Disorders Using A Bleeding Disorders Registry | Nur Insyirah Abdul Kadir | ![]() |
![]() |
|||
PB-771 | DELPHI expert consensus statements on clinical evaluation of bleeds in patients with acquired haemophilia | Andreas Tiede | ![]() |
![]() |
|||
PB-773 | Acquired Factor XI deficiency: diagnosis and evolution. A case reports | Marina Sol Lopez | ![]() |
![]() |
|||
PB-777 | Rare Bleeding Disorders in Lebanon: Clinical and Molecular Data and Creation of a Registry | Roula Farah | ![]() |
![]() |
|||
PB-778 | Factor XIII Deficiency. A Case Report at Hospital Infantil de México Federico Gómez | Aida Mashenka Moreno González | ![]() |
![]() |
|||
PB-779 | Hypodysfibrinogenemia in a Patient with Aortic Valve Thrombosis and Stroke: Diagnosis and Evolution. Identification of a Novel Heterozygous Fibrinogen Gamma Chain Mutation | Veronica Privitera | ![]() |
![]() |
|||
PB-780 | vWF Activity is Associated with Bleeding Symptoms in Essential Thrombocythemia | Jun Yamanouchi | ![]() |
![]() |
|||
PB-782 | Low von Willebrand Levels Do Not Predict Bleeding in Children Undergoing Tonsillectomy | Veronica Flood | ![]() |
![]() |
|||
PB-783 | Bleeding Symptoms and von Willebrand Factor Levels in Thai Patients: 30-year Experience in a Tertiary Care Center | Chaphatai Moonla | ![]() |
![]() |
|||
PB-785 | Investigation of the Epidemiology of VWD in Patients Attending the Royal Hospital, Muscat, Oman | Rashid Al Ghaithi | ![]() |
![]() |
|||
PB-786 | Desmopressin Plasma Concentration Does Not Correlate with VWF and FVIII Response in von Willebrand Disease | Jessica Heijdra | ![]() |
![]() |
|||
PB-787 | The Management of Patients with von Willebrand Disease (VWD) Undergoing Surgery by Using a Pure Plasma Derived VWF is Easy, Efficient and Safe | Jenny Goudemand | ![]() |
![]() |
|||
PB-788 | Effect of pathologic flow on von Willebrand factor cleavage by ADAMTS13 | Maria Bortot | ![]() |
![]() |
|||
PB-789 | Acquired von Willebrand Syndrome during Mechanical Circulatory Support and Extracorporeal Membrane Oxygenation: Rapid Onset and the Demand for Point of Care Testing | Andreas Straub | ![]() |
![]() |
|||
PB-790 | Exploration and treatment strategies for gastrointestinal bleeding in VWD over a 3-year period: A national survey from the French reference center for VWD | Antoine Rauch | ![]() |
![]() |
|||
PB-791 | Genotype-phenotype and pathophysiological mechanisms involved in patients with von Willebrand disease (VWD) type 2A and 2M according to domains affected by genetic clinical-grade variants (CGV) | Adriana Inés Woods | ![]() |
![]() |
|||
PB-792 | Gastrointestinal Angiodysplasia and Von Willebrand Disease: Our Experience of Managing Challenging Bleeding | Gary Benson | ![]() |
![]() |
|||
PB-793 | A Novel Mechanism in Severe Type 1 VWD: a Heterozygous Splicing Mutation Causes Exon 26 Skipping and Increases VWF Clearance | Mattia Ferrarese | ![]() |
![]() |
|||
PB-794 | Annual Bleeding Rates with Efficacy/Safety of the VWF Concentrates used On Demand or under Secondary Long-Term Prophylaxis in a large cohort of centrally confirmed VWD3 patients: results of 24-month prospective observation in 169 cases enrolled into the 3 | Augusto B Federici | ![]() |
![]() |
|||
PB-795 | Successful non-surgical management and use of thrombopoietin receptor agonist in a case of spleen injury in a young girl with von Willebrand disease type 2B | Valerie Proulle | ![]() |
![]() |
|||
PB-796 | Pathophysiology underlying genetic clinical-grade variants (CGV) responsible for the phenotypes type 2A and 2M of von Willebrand disease (VWD) | Adriana Ines Woods | ![]() |
![]() |
|||
PB-797 | Platelet Transfusion in von Willebrand Disease type IIB in a Family with Normal Platelet Counts | Kim Schafer | ![]() |
![]() |
|||
PB-798 | Variable Reproducibilty of Type 2 VWD Diagnoses | Veronica Flood | ![]() |
![]() |
|||
PB-800 | Type 1 VWD Caused by a Novel Dominant p.Thr274Pro Mutation Localized in VWF Propeptide | Maria Teresa Pagliari | ![]() |
![]() |
|||
PB-802 | BMI is an important determinant of VWF and FVIII levels in patients with von Willebrand disease | Ferdows Atiq | ![]() |
![]() |
|||
PB-806 | Acquired type 3-like von Willebrand syndrome complicated with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia | Jie Yin | ![]() |
![]() |
|||
PB-807 | Management of Postpartum Haemorrhage in a Woman with Type 2B Von Willebrand Disease | Samuel Ackroyd | ![]() |
![]() |
|||
PB-812 | Quantification of VWF Propeptide Release before and after Desmopressin in von Willebrand Disease and Hemophilia A | Jessica Heijdra | ![]() |
![]() |
|||
PB-814 | Sequencing of VWF Gene in Patients with von Willebrand Disease: Our First Experience in Slovakia | Jana Zolkova | ![]() |
![]() |
|||
PB-815 | Acquired von Willebrand syndrome and hematological malignancies | Yamina Ouarhlent | ![]() |
![]() |
|||
PB-816 | Detecting Structural Disorder in Multimeric von Willebrand Factor | Matthew Auton | ![]() |
![]() |
|||
PB-817 | Von Willebrand Disease: An International Survey Assessing Important Topics for Decision-making | Nathan T. Connell | ![]() |
![]() |
|||
PB-818 | DDAVP Challenge Test in Patients with von Willebrand Disease Type 1 (VWD1) and Low von Willebrand Factor (Low VWF): Analysis of 616 Patients | Mara Agazzoni | ![]() |
![]() |
|||
PB-822 | Some Haemostatic Parameters, Full Blood Count and Relative Plasma Viscosity of Blood Donors in Calabar Metropolis | Dorathy Chioma Okpokam | ![]() |
![]() |
|||
PB-825 | Comparison of mindset between the medical doctors and the staffs of genetic counseling about support of hemophilia carriers in Japan | Tomie Fujii | ![]() |
![]() |
|||
PB-826 | THE EFFECT BETWEEN BANGUN-BANGUN LEAVES ETHANOL EXTRACTS (EDBB) AND CARROTS JUICE (CJ) AS ANALGETIC ON MICE INDUCED BY ACETIC ACID | Yunita Sari Pane | ![]() |
![]() |
|||
PB-827 | It takes a village… The implementation of a multidisciplinary clinic review for children and adolescents with bleeding disorders | Jaime Chase | ![]() |
![]() |
|||
PB-828 | Current Nursing Workloads and Implications for the Future within Haemophilia Treatment Centres in Australia | Susan Jane Webzell | ![]() |
![]() |
|||
PB-829 | National benchmarking of Paediatric Haemophilia Treatment Centres | Stacey Hutchison | ![]() |
![]() |
|||
PB-830 | The nurse´s role in training others to administer missing factor concentrates to patients with haemophilia | Pawel Laguna | ![]() |
![]() |
|||
PB-832 | Ichec: Refining the Pediatric Bleeding Assessment Tool | Karin Fijnvandraat | ![]() |
![]() |
|||
PB-833 | MYH9 Related Disease Mimicking Immune Thrombocytopenia | Bunchoo Pongtanakul | ![]() |
![]() |
|||
PB-835 | Does a Therapeutic Early Morning ACT and APTT Correlate with the Absence of Bleeding or Thrombotic Complications within the Next 24 Hours in Paediatric Patients on ECMO? | Gabrielle Lee | ![]() |
![]() |
|||
PB-836 | Circumcision Experience in Children with Bleeding Disorder: Samsun Circumcision Protocol | Canan Albayrak | ![]() |
![]() |
|||
PB-837 | A Development of Anaphylactoid Reaction in a Child with Congenital FVII Deficiency and Inhibitor: The First Reported Case | Aysegul Unuvar | ![]() |
![]() |
|||
PB-838 | Hypofibrinogenemia: A novel long deletion of the fibrinogen beta chain causing mucocutaneous bleeding | Darintr Sosothikul | ![]() |
![]() |
|||
PB-839 | Kasabach-Merritt phenomenon in an infant: Tufted angioma or kaposiform hemangioendothelioma | Rumeysa Tuna | ![]() |
![]() |
|||
PB-841 | Impact of Hematology Involvement on Adolescents Admitted for Acute Heavy Menstrual Bleeding | Viia Anderson | ![]() |
![]() |
|||
PB-842 | Acquired von Willebrand Syndrome (aVWS) - A Complication in Pediatric Patients with Congenital Heart Diseases | Ivonne Wieland | ![]() |
![]() |
|||
PB-843 | Hemostasis Dysfunctions in Routine Otolaryngology Preoperative Laboratory Screening Tests - An One Year Retrospective Pediatric Study | Rute Preto | ![]() |
![]() |
|||
PB-845 | Therapeutic Aspects, Determining the Outcome of Deep Veins Thrombosis (DVT) in Children with Hematological Diseases | Darya Fedorova | ![]() |
![]() |
|||
PB-846 | Genetic and Clinical Determinants Influencing Warfarin Dosing in Thai Children and Adolescents | Premmika Intapun | ![]() |
![]() |
|||
PB-847 | Septic Dural Sinus Thrombosis in Children | Patcharee Komvilaisak | ![]() |
![]() |
|||
PB-848 | Central Venous Catheter-associated Thromboembolism: Still a Frequent Complication with No Reliable Predictive Indicators in Young Children with Diabetic Ketoacidosis | Gary Woods | ![]() |
![]() |
|||
PB-849 | Effectiveness and Safety of Primary Thromboprophylaxis in Children with Cancer: A Systematic Review of the Literature and Network Meta-analysis | Leonardo R. Brandão | ![]() |
![]() |
|||
PB-851 | Is There Any Improvement of the Coagulation Imbalance in Sickle Cell Disease after Hematopoietic Stem Cell Transplantation? | Anne Demulder | ![]() |
![]() |
|||
PB-854 | Neonatal and Pediatrics Optimal Anticoagulant Therapy and Role of Clinical Pharmacist - A Medication Safety Model in Developing Country | Gul Ambreen | ![]() |
![]() |
|||
PB-855 | Predictive Value of D-dimers in the Diagnosis of Suspected Acute Limb Deep Vein Thrombosis in Children: A Prospective Study | Maria Laura Avila | ![]() |
![]() |
|||
PB-857 | Thromboembolism and Bleeding in Congenital Diaphragmatic Hernia | Leonardo Brandao | ![]() |
![]() |
|||
PB-858 | Highly Discordant Laboratory-based Aspirin Resistance Rates after Pediatric Organ Transplantation May Reflect Significant Cyclooxygenase 1-independent Thromboxane Production Postoperatively | Lori Luchtman-Jones | ![]() |
![]() |
|||
PB-859 | Bleeding and Clotting in Children on ECMO at the Royal Children´s Hospital: A Two Year Summary | Suelyn Van Den Helm | ![]() |
![]() |
|||
PB-860 | Comparison of alpha-1-antitrypsin glycoform content in newborns and adults | Helen Atkinson | ![]() |
![]() |
|||
PB-861 | Platelet Phenotype and Function in Paediatric Extracorporeal Membrane Oxygenation (ECMO) Circuits | Hui Ping Yaw | ![]() |
![]() |
|||
PB-862 | Endothelial and Platelet Activations in a-thalassemia Diseases | Pankamol Sirivadhanakul | ![]() |
![]() |
|||
PB-864 | Transition of Care for Adult and Pediatric Patients with Venous Thromboembolism - An American Thrombosis Hemostasis Network (ATHN) Project | Maria DeSancho | ![]() |
![]() |
|||
PB-866 | Single Nucleotide Polymorphisms in Promoter Region of PROC gene are Associated with Low Protein C Activity but not Increase Risk of Thromboembolism in Pediatric Population | Natsumon Udomkittivorakul | ![]() |
![]() |
|||
PB-867 | Use of antithrombin concentrate in acquired antithrombin deficiency in acutely unwell children receiving unfractionated heparin -single centre experience | Deepa Jayakody Arachchillage | ![]() |
![]() |
|||
PB-868 | First Korean Case of Thrombocythemia 1 (THCYT1) with THPO Mutation (c.13+1G>A, splicing) Diagnosed by Targeted Exome Sequencing | Do-Hoon Kim | ![]() |
![]() |
|||
PB-869 | Comparison of the thromboelastographic profile of paired placental and neonatal blood samples | Erica Scalambrino | ![]() |
![]() |
|||
PB-870 | Cerebral Sinus Venous Thrombosis In One Institution | Patcharee Komvilaisak | ![]() |
![]() |
|||
PB-872 | Low dose anticoagulation in children with Kawasaki disease and large coronary artery aneurysms: our experience at Chandigarh, North India | Surjit Singh Samlok | ![]() |
![]() |
|||
PB-874 | A Retrospective Review of Antithrombotic Therapy in Paediatric Patients with Moyamoya Disease | Nadia Poci | ![]() |
![]() |
|||
PB-875 | Thrombotic Events in Very Low Birth Weight Infants Treated in an Intensive Care Setting | Athis Arunachalam | ![]() |
![]() |
|||
PB-876 | Low Bone Mass/Osteoporosis in Thai Children and Adolescents Taking Long-term Warfarin | Thanyabun Akkharawanasakul | ![]() |
![]() |
|||
PB-878 | Multidisciplinary Approach to Pediatric Thrombosis; Istanbul Pediatric Thrombosis (I-PeT) Study Group Experience | Zeynep Karakas | ![]() |
![]() |
|||
PB-879 | Symptomatic and Incidental VTE in Children Differs in Epidemiology and Outcomes | Daria Fedorova | ![]() |
![]() |
|||
PB-880 | Results of an International Survey of Practice in the Diagnosis And Management of Pediatric Pulmonary Embolism | Madhvi Rajpurkar | ![]() |
![]() |
|||
PB-881 | Thrombolytic Therapy in Preterm Neonates: experience of a single center | Priscila Grizante-Lopes | ![]() |
![]() |
|||
PB-882 | Congenital protein C deficiency: a family report from Argentina | David A. Veron | ![]() |
![]() |
|||
PB-883 | Inferior vena cava filters (IVCF) in children with venous thromboembolism (VTE): a 26-year prospective cohort from a single tertiary center in Argentina | Carolina Cervio | ![]() |
![]() |
|||
PB-885 | Prothrombotic states as a risk factor for stroke among pediatric patients | Olivera Serbic | ![]() |
![]() |
|||
PB-887 | Hemostatic Complications in Pediatric Extra Corporeal Membrane Oxygenation: the Role of Rotational Thromboelastometry | Joppe Geert Frederik Drop | ![]() |
![]() |
|||
PB-888 | Congenital Protein C Deficiency: Unfamiliarity of this Condition led to Unfavorable Results in a 14 Year old Girl | Madlen Reschke | ![]() |
![]() |
|||
PB-890 | The impact of the volume of mediastinal lymphadenopathy on venous thromboembolism in children with lymphoma | Daria Fedorova | ![]() |
![]() |
|||
PB-891 | Analysis of Stroke in Neonates and Children: Single Center Experience | Hale Ören | ![]() |
![]() |
|||
PB-892 | Enriched Variants of Coagulation, Platelet and Related Genes are Common in Adolescents with Idiopathic Occlusive Proximal Deep Vein Thrombosis | Beth Warren | ![]() |
![]() |
|||
PB-894 | Neonatal Inferior Vena Cava Syndrome: An Evidence-based Systematic Review of the Literature | Paul Thuan Tieu | ![]() |
![]() |
|||
PB-895 | Incidence and Risk Factors for Peripherally Inserted Central Catheter-related Venous Thrombosis in Critically-ill Children with Cardiac Disease: A Retrospective Single-center Case-control Study | Eva Hortas | ![]() |
![]() |
|||
PB-896 | Use of Low Molecular Weight Heparins in Pediatric Thromboembolism: A Retrospective Descriptive Study | Sarah Brouche | ![]() |
![]() |
|||
PB-897 | A 10-year Case-control Study on the Risk Factors for Neonatal Portal Vein Thrombosis | Tuan Nguyen | ![]() |
![]() |
|||
PB-898 | An Institutional Analysis of Pediatric Patients with Upper Extremity Deep Vein Thrombosis in the Context of Thoracic Outlet Syndrome | Aamir Ameen Sholapur | ![]() |
![]() |
|||
PB-899 | Clinical Course of Lemierre Syndrome in the Contemporary Era: Results of a Patient-level Analysis of 715 Patients | Luca Valerio | ![]() |
![]() |
|||
PB-900 | Monitoring of Thromboprophylaxis in Children with Fontan Procedure: Experience in an Argentinian Hospital | Silvina Romano | ![]() |
![]() |
|||
PB-902 | International Pediatric Thrombosis Network: Advancing the Field of Pediatric Thrombosis | C.Heleen van Ommen | ![]() |
![]() |
|||
PB-904 | The Effect of Hyperbilirubinemia and Phototherapy on Apoptotic, Platelet-derived, Endothelial-derived, and Tissue Factor Positive Microparticle Levels in Neonates | Hale Ören | ![]() |
![]() |
|||
PB-905 | Development of an Umbilical Cord and Pediatric Plasma Bank | Helen Atkinson | ![]() |
![]() |
|||
PB-906 | Pediatric May-Thurner Syndrome - A Systematic Review | Leonardo Brandao | ![]() |
![]() |
|||
PB-908 | Effective and Well Tolarated Treatment with a Direct Oral Anticoagulant in a Young Patient with the Vena Cava inferior Agenesis and a Deep Vein Thrombosis | Tomas Kuhn | ![]() |
![]() |
|||
PB-909 | Anticoagulation Management and Outcomes in Thrombocytopenic Cancer Patients with Atrial Fibrillation | Avi Leader | ![]() |
![]() |
|||
PB-910 | Safety of Using Antiplatelet Drug in Dengue Hemorrhagic Fever with Thrombocytopenia: A Retrospective Study | Andree Kurniawan | ![]() |
![]() |
|||
PB-914 | Major bleeding after a gynecological operation in patient with essential thrombocythemia - Case report | Marija Skoko | ![]() |
![]() |
|||
PB-915 | Reduced platelet function in patients with liver cirrhosis | Andrea Artoni | ![]() |
![]() |
|||
PB-917 | Concomitant Immune Thrombocytopenia and Positive for JAK2 V617F Mutation in a Patient: Case Report and Literature Review | Xiaofan Liu | ![]() |
![]() |
|||
PB-919 | Using flow cytometry to improve the risk assessment and management of bleeding in subjects with acquired thrombocytopenia | David Connor | ![]() |
![]() |
|||
PB-921 | Platelet disorders, acquired with thermally oxidized mixed vegetable oils in low and high doses - In animal model | Gul Ambreen | ![]() |
![]() |
|||
PB-926 | Whole Blood Mepacrine Flow Cytometric Determination of Platelet Dense Granules: Difficulties in Establishing a Reference Range and Interpreting Results | Timothy Brighton | ![]() |
![]() |
|||
PB-927 | Whole Mount Electron Microscopy for Determination of Platelet Dense Granules: Which Parameter to Measure to Detect Dense Granule Deficiency? | Timothy Brighton | ![]() |
![]() |
|||
PB-928 | The First Homozygous GNE Variant in the P-loop of the ManNAc Kinase Domain Causes Severe Macrothrombocytopenia and Bleeding | Marie-Christine Morel-Kopp | ![]() |
![]() |
|||
PB-929 | Outcome of an Enhanced Diagnostic Pipeline for Patients Suspected for Inherited Thrombocytopenia | Eva Leinoe | ![]() |
![]() |
|||
PB-930 | Prospective Comparison of Whole Mount Electron Microscopy and Mepacrine Based Flow Cytometric Assay for Determination of Platelet Dense Granules and Platelet Dense Granule Deficiency | Timothy Brighton | ![]() |
![]() |
|||
PB-932 | How Many Shades of Grey in the Gray Platelet Syndrome | Marie-Christine Morel-Kopp | ![]() |
![]() |
|||
PB-933 | Whole Exome Sequencing for Diagnosis of Hereditary Platelet Disorders | Ponlapat Rojnuckarin | ![]() |
![]() |
|||
PB-934 | Integrin ß3 Deficiency Disrupts Triglyceride (TG) Metabolism Owing to an Impaired Lipoprotein Lipase (LPL) Secretion | Xiaodong Xi | ![]() |
![]() |
|||
PB-937 | Glycoprotein VI Mutation is Widespread in the Chilean Population | Amanda Dalby | ![]() |
![]() |
|||
PB-939 | First Spanish Registry of Inherited Platelet Disorders [RETPLAC] | Jose Rivera | ![]() |
![]() |
|||
PB-941 | MYH9 Disorders in Thailand: Pediatric Case Series from Thai Macrothrombocytopenia Study Group | Rungrote Natesirinilkul | ![]() |
![]() |
|||
PB-942 | MYH9 gene mutation screening in students with macrothrombocytes/ thrombocytopenia who are attending in hearing impaired schools in Istanbul | Tiraje Celkan | ![]() |
![]() |
|||
PB-944 | Platelet Function Testing: Current Practice among Clinical Centers in the Nordic Countries | Riitta Lassila | ![]() |
![]() |
|||
PB-945 | The utility of flow cytometric platelet forward scatter as an alternative to mean platelet volume | David Connor | ![]() |
![]() |
|||
PB-946 | Correlation between mutations and clinical features in patients with essential thrombocythemia | Mankai Ju | ![]() |
![]() |
|||
PB-949 | Studies on Regulation of Thromboxane Production by PCTP and RUNX1 in Megakaryocytic cells | A Koneti Rao | ![]() |
![]() |
|||
PB-950 | Capillary Blood Reference Intervals for Platelet Counts (PLT) and Related Parameters from Full Term Healthy Neonates in China and Influences of Gender, Gestational Age and Postnatal Age on PLT | Qun Hu | ![]() |
![]() |
|||
PB-951 | Reported Outcome and Quality of Life of Children with Chronic Immune Thrombocytopenia Treated with Thrombopoietin Receptor Agonist | Nongnuch Sirachainan | ![]() |
![]() |
|||
PB-952 | Assessment of Platelet Aggregation in Umbilical Cord Blood Using Multiple Electrode Aggregometry | Sara Joan Israels | ![]() |
![]() |
|||
PB-953 | Targeting DNT/Treg axis, Sirolimus is operative in thrombocytopenia caused by autoimmune lymphoproliferative syndrome (ALPS)/ALPS-like syndrome: results of a single centre experience | Hao Gu | ![]() |
![]() |
|||
PB-954 | Aspirin Unresponsiveness in Pediatric Patients: Incidence and Methods of detection | Darintr Sosothikul | ![]() |
![]() |
|||
PB-956 | Immune Thrombocytopenia in Childhood: A 15 Year Single Center Experience | Alkistis Adramerina | ![]() |
![]() |
|||
PB-958 | Post-translational polymodification of the C-terminal Tail of TubB1 Regulates Motor Protein Activity in Platelet Production and Function | Neil Morgan | ![]() |
![]() |
|||
PB-959 | Impact of intracellular calcium imbalance in megakaryocytic leukaemia cells uncovered through the deletion of NMDA receptors | James Hearn | ![]() |
![]() |
|||
PB-960 | Human Bone Marrow Primary Endothelial Cells Play a Key Role in the Latest Phase of Megakaryocyte Differentiation | Anita Eckly | ![]() |
![]() |
|||
PB-961 | TLT-1 Expression during Megakaryocyte Differentiation | Angela Doerr | ![]() |
![]() |
|||
PB-965 | Potential of anthocyanins to reduce thrombotic risk by alleviating platelet activity | Almottesembellah Gaiz | ![]() |
![]() |
|||
PB-967 | Perfusion Conditions Control the Morphology of Thrombus Growth at High Shear Rates | Shunichi Kobayashi | ![]() |
![]() |
|||
PB-968 | Evaluation of Platelet Membrane Potential in Assessing the Risk of Thrombosis in Patients with Chronic Myeloproliferative Neoplasms | Viola Popov | ![]() |
![]() |
|||
PB-970 | The Effect of Procoagulant Platelets on Different Aspects of Hemostasis | Sofia Ramstrom | ![]() |
![]() |
|||
PB-974 | Do donor attributes influence platelet quality following ex vivo storage? | Dianne E. Van Der Wal | ![]() |
![]() |
|||
PB-975 | Variation of platelet dependent thrombin generation in phenotypes of acute venous thromboembolism | Marina Panova-Noeva | ![]() |
![]() |
|||
PB-976 | A Synthetic Triple Helical Collagen Peptide as a New Agonist for Flow Cytometric Measurement of GPVI Specific Platelet Activation | Yaqiu Sang | ![]() |
![]() |
|||
PB-977 | A novel rapid method of red blood cells and platelets permeabilization and staining for flow cytometry analysis | Marie-Christine Alessi | ![]() |
![]() |
|||
PB-979 | Platelet-specific factor XIII-A: A novel role in the regulation of platelet function | Jo Mitchell | ![]() |
![]() |
|||
PB-983 | Platelet storage lesion: Proteomic analysis of extracellular vesicles derived from platelets treated with Mirasol | Maria N. Barrachina | ![]() |
![]() |
|||
PB-984 | Platelet size subpopulations differ in protein constitution and mRNA profile | Aneta Wrzyszcz | ![]() |
![]() |
|||
PB-985 | The Role of Platelet Membrane Fluidity in Expressions of Platelet Receptors and Platelet Derived Microparticles in Patients with Chronic Myeloproliferative Neoplasms | Viola Maria Popov | ![]() |
![]() |
|||
PB-986 | Synergy in Platelet Activation and Thrombus Formation in Mice with a Combined Deletion of PECAM-1 and Ceacam1 | Fahd A. Kuriri | ![]() |
![]() |
|||
PB-987 | Human Fc?RIIa receptor contributes to E.coli-induced thrombocytopenia in vivo | Dermot Cox | ![]() |
![]() |
|||
PB-988 | Heme induces platelet aggregation via two ITAM receptors: implications in rhabdomyolysis-induced acute kidney injury | Nagaharu Tsukiji | ![]() |
![]() |
|||
PB-989 | Metabolomics of platelet activation with normoxia and hypoxia | Nathan Clendenen | ![]() |
![]() |
|||
PB-992 | Coenzyme Q10 Attenuates Platelet Function through Targeting cAMP/PKA Pathway | Yan Yang | ![]() |
![]() |
|||
PB-993 | The Differential Requirement of the Btk Kinase Domain Downstream of ITAM and HemITAM Signalling | Sophie H Nock | ![]() |
![]() |
|||
PB-994 | Evidence for a PI3-kinase-independent pathway regulating ADP-induced Rap1b activation in platelets | Carol Dangelmaier | ![]() |
![]() |
|||
PB-995 | Branched-Chain Amino Acids Facilitated Thrombosis by Enhancing the Propionylation of TMOD3 in Platelets | Yanyan Xu | ![]() |
![]() |
|||
PB-996 | Effect of recombinant human lactoferrin, isolated from transgenic goats, on platelet aggregation and Ca2+-response | Ekaterina Shamova | ![]() |
![]() |
|||
PB-999 | Platelet Integrin aIIbß3-dependent Outside-in Signaling Is Regulated by Apoptosis Signal-regulating Kinase 1 through p38 MAP Kinase Signaling | Meghna Naik | ![]() |
![]() |
|||
PB-1000 | Fibrin modulates shear-induced NETosis in sterile occlusive thrombi formed under arterial hemodynamic flow | Scott Diamond | ![]() |
![]() |
|||
PB-1001 | Characterization of the P-selectin-TLT-1 Null Mouse | A. Valance Washington | ![]() |
![]() |
|||
PB-1002 | The VWF-GPIb interaction mediates thrombo-inflammation in experimental stroke via recruitment of monocytes, neutrophils and T-cells to the brain | Frederik Denorme | ![]() |
![]() |
|||
PB-1003 | Effect of Ultrapure Bacterial Lipopolysaccharides on the Modulation of Platelet Activation | Thomas Vallance | ![]() |
![]() |
|||
PB-1004 | The Antimicrobial Cathelicidin CRAMP Augments Platelet Activation during Psoriasis in Mice | Sakthivel Vaiyapuri | ![]() |
![]() |
|||
PB-1005 | Platelet Rich Plasma for Acute Achilles Tendon Rupture: A Double-Blind Multicentre Randomized Placebo-controlled Trial (PATH-2) | Paul Harrison | ![]() |
![]() |
|||
PB-1008 | Inferior Vena Cava Filters in Cancer Patients: Indications and Outcome | Anila Rashid | ![]() |
![]() |
|||
PB-1009 | A Comparison of Venous Thromboembolism (VTE) and Arterial Events between Ixazomib, Lenalidomide and Dexamthosone (ILD) and Lenalidomide and Dexamethosone (LD) Chemotherapy in Multiple Myeloma: Single Centre Experience | Zara Sayar | ![]() |
![]() |
|||
PB-1010 | Risk of Upper Limb Venous Thromboembolism from Peripherally Inserted Catheters in Cancer Patients Receiving Chemotherapy | Hiu Lam Agnes Yuen | ![]() |
![]() |
|||
PB-1011 | A Case of Cryocrystalglobulinemia with Microvascular Embolization as the First Manifestation and Literature Review | Ning Tang | ![]() |
![]() |
|||
PB-1012 | Patients with Primary CNS Lymphoma Have High Rates of Venous Thromboembolism during R-MPV Chemotherapy | Hiu Lam Agnes Yuen | ![]() |
![]() |
|||
PB-1014 | Coagulation Factors and Natural Anticoagulants in Polycythemia Vera Patients, Relation with JAK2V617F Mutation Load | Natalya Silina | ![]() |
![]() |
|||
PB-1015 | Improving Care for Patients with Cancer Associated Thrombosis in the Netherlands Using Patients´, Caregivers´ and Health Care Professionals´ Experiences | Asiong Jie | ![]() |
![]() |
|||
PB-1017 | Thromboprophylaxis in the Perioperative Patient in Patients with Breast Cancer on Tamoxifen | Beverley Hunt | ![]() |
![]() |
|||
PB-1018 | Risk of Venous Thromboembolism in Hospitalized Medical Cancer Patients with Midline and Peripherally Inserted Central Catheters | Scott Kaatz | ![]() |
![]() |
|||
PB-1019 | Management of Superficial Venous Thrombosis in Unevaluated Situations: Cancer, Severe Chronic Renal Failure, Pregnancy and Post-partum | Laurent Bertoletti | ![]() |
![]() |
|||
PB-1020 | Venous Thromboembolism in Hospitalized Medical Cancer Patients with and without Chemotherapy Infusion through Peripherally Inserted Central Catheters | Scott Kaatz | ![]() |
![]() |
|||
PB-1021 | Accuracy of the Ottawa Score in Risk Stratification of Recurrent Venous Thromboembolism in Patients with Cancer-associated Venous Thromboembolism. A Systematic Review and Meta-analysis | Aurelien Delluc | ![]() |
![]() |
|||
PB-1022 | Clinical Risk Prediction Model for Venous Thromboembolism (VTE) in Allogeneic Blood or Marrow Transplant (BMT) Survivors | Radhika Gangaraju | ![]() |
![]() |
|||
PB-1024 | Evaluation of Outpatient Management in Patients with Cancer-associated Venous Thromboembolism | Stephan V. Hendriks | ![]() |
![]() |
|||
PB-1027 | Global assays (TEG and ETP) and biomarkers in stratifying thromboembolic risk in patients with lung and gastrointestinal cancer undergoing chemotherapy or chemoradiotherapy - a subsequent analysis from the BIOTEL (lung cancer) and BIOTEGIC (gastrointestin | Nora Lee | ![]() |
![]() |
|||
PB-1028 | Association of complete blood count parameters, d-Dimer and soluble P-selectin with risk of arterial thromboembolism in patients with cancer | Ella Grilz | ![]() |
![]() |
|||
PB-1029 | Relative Risk of Arterial and Venous Thromboembolism in Persons with Cancer versus Persons without Cancer - A Nation-Wide Analysis | Ella Grilz | ![]() |
![]() |
|||
PB-1030 | Apixaban as treatment for Cancer Related Venous Thrombosis - A single arm interventional study | Trine-Lise Hannevik | ![]() |
![]() |
|||
PB-1031 | Superficial Vein Thrombosis and Cancer | Jana Hirmerova | ![]() |
![]() |
|||
PB-1035 | Thromboses in Hodgkin Lymphoma Are Caused by Acquired Risk Factors | Nilgun Sayinalp | ![]() |
![]() |
|||
PB-1036 | Von Willebrand Factor Levels Are Increased in Polycythemia Vera and Can Be Predicted by Erythrocyte Counts | Monica Sacco | ![]() |
![]() |
|||
PB-1037 | The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE Cancer study | Floris T.M. Bosch | ![]() |
![]() |
|||
PB-1038 | Incidence, Risk Factors and Clinical Outcomes of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the BACAP Cohort | Corinne Frere | ![]() |
![]() |
|||
PB-1039 | Bleeding in the Prevention of Cancer-Associated Venous Thromboembolism: Secondary Analysis of the AVERT Study | Lana A. Castellucci | ![]() |
![]() |
|||
PB-1040 | Incidence of venous thromboembolism in patients with advanced stage cervico-uterine cancer | Gabriela Cesarman-Maus | ![]() |
![]() |
|||
PB-1044 | Portal Vein Thrombosis as a Prognostic Factor for Survival Rate in Liver Cirrhosis with Hepatocellular Carcinoma Patients | Andree Kurniawan | ![]() |
![]() |
|||
PB-1045 | Incidentally detected venous thromboembolism in cancer patients: Results from the Hokusai VTE Cancer trial | Frits Mulder | ![]() |
![]() |
|||
PB-1046 | The performance of the Ottawa score in predicting recurrence in cancer patients with incidental pulmonary embolism | Frits I. Mulder | ![]() |
![]() |
|||
PB-1048 | Role of microRNAs in venous thromboembolic disease of patients with lung cancer | Julia Oto | ![]() |
![]() |
|||
PB-1050 | Prospective Registry of Cancer and Events Involving Venous Thromboembolism (PERCEIVE): 12-month outcomes | Gloria Petralia | ![]() |
![]() |
|||
PB-1052 | Catheter Related Thrombosis in Patients with Hematologic Malignancies: A Venous ThromboEmbolism Network US (VENUS) Multicenter Retrospective Cohort Study | Lisa Baumann Kreuziger | ![]() |
![]() |
|||
PB-1053 | Evaluation of Platelet Parameters in a Prospective Cohort of Healthy Subjects in Relation to Cancer Diagnosis | Marina Marchetti | ![]() |
![]() |
|||
PB-1055 | Cancer associated thrombosis and direct oral anticoagulants: a meta-analysis of randomised clinical trials | Marilyn Rees | ![]() |
![]() |
|||
PB-1056 | Incidental Pulmonary Embolism (IPE): Clinical Implication of Contemporaneous Cancer Response Status and Swiftness of PE Reporting | Anthony Maraveyas | ![]() |
![]() |
|||
PB-1057 | Incidental Pulmonary Embolism (I-PE): How Important Are Abnormal Conventional Lab Indices in Predicting Clinical Outcomes? | Farzana Haque | ![]() |
![]() |
|||
PB-1061 | Perioperative Management of Direct Oral Anticoagulants: A Single Centre Observational Study | Stephanie P´ng | ![]() |
![]() |
|||
PB-1062 | Comparison of Outcomes in Patients Undergoing Periprocedural Interruption of Warfarin or Direct Oral Anticoagulants | Brian Haymart | ![]() |
![]() |
|||
PB-1063 | A Retrospective Analysis of the real-world use of Idarucizumab at Two Tertiary Care Centres in Toronto, Canada | Jameel Abdulrehman | ![]() |
![]() |
|||
PB-1064 | Reversal of warfarin using low dose Prothromplex Total, a 4-factor prothrombin complex and its implications on fix-dosing regimens | Shu Hui Yeang | ![]() |
![]() |
|||
PB-1065 | Perioperative Management of Anticoagulant Therapies in Elderly Patients Undergoing Orthopedic Surgery: Preliminary Results from the ORTHO-START Registry | Elvira Grandone | ![]() |
![]() |
|||
PB-1066 | Idarucizumab for dabigatran reversal, the first 6 months in a tertiary center | Matt Wheeler | ![]() |
![]() |
|||
PB-1067 | Use of Low Molecular Weight Heparin during the Postoperative Period: Perioperative Management Plan of Patients Treated with Direct Oral Anticoagulants | Desiree Campoy | ![]() |
![]() |
|||
PB-1069 | Oral Anticoagulant-associated Bleeding Requiring Hospitalization: Incidences, Risk Factors and Outcomes | Kochawan Boonyawat | ![]() |
![]() |
|||
PB-1070 | Risk for Major and Fatal Bleeding After Discontinuing Oral Anticoagulation for Unprovoked Venous Thromboembolism: Systematic Review and Meta-analysis | Faizan Khan | ![]() |
![]() |
|||
PB-1071 | Excessive Bleeding on Dabigatran Therapy Possibly Due to Genetically Predisposed Low Transport Activity of ABCB1 - A Case Report | Silva Zupancic-Šalek | ![]() |
![]() |
|||
PB-1072 | Does INR predict bleeding events in children on warfarin? A longitudinal study | Natsaruth Songthawee | ![]() |
![]() |
|||
PB-1073 | What is the incidence and severity of abnormal uterine bleeding associated with rivaroxaban in the treatment of VTE and is there an impact on treatment satisfaction? Early results from the ´Follow-up In Rivaroxaban patients in Setting of Thromboembolism´ | Vicky Speed | ![]() |
![]() |
|||
PB-1075 | Analysis of Bleeding Events on Prophylactic Rivaroxaban in the CASSINI Study | Gerald Soff | ![]() |
![]() |
|||
PB-1076 | Risk of bleeding according to renal function in patients with venous thromboembolic disease under treatment with enoxaparin | Fernando Chuliber | ![]() |
![]() |
|||
PB-1077 | Resumption of Anticoagulant Therapy After Anticoagulant-Related Bleeding: A Population-Based Cohort Study | Deborah Siegal | ![]() |
![]() |
|||
PB-1080 | Management and outcome of bleeding complications in patients treated with direct oral anticoagulants - updated interim analysis | Roisin Bavalia | ![]() |
![]() |
|||
PB-1081 | Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism | Ingrid Bistervels | ![]() |
![]() |
|||
PB-1083 | Factor Xa Inhibitor Antidote, Andexanet Alfa Differentially Reverses the Effects of Apixaban, Betrixaban, Edoxaban and Rivaroxaban | Fakiha Siddiqui | ![]() |
![]() |
|||
PB-1084 | Management of Oral Anticoagulant Reversal Prior to Emergency Surgery: Are we Following Guidelines in the United States? | Jerrold Levy | ![]() |
![]() |
|||
PB-1085 | Efficacy of Idarucizumab to Reverse the Anticoagulant Effect of Dabigatran in Emergency Situations | Laura Francisca Ávila Idrovo | ![]() |
![]() |
|||
PB-1086 | Effect of 4F-PCC Weight Capped Dosing on INR Reversal for Patients with Life-threatening Bleeding or Requiring Emergent Surgery | Jessica Rimsans | ![]() |
![]() |
|||
PB-1088 | Coordinating Emergent Procedures after Factor Xa Inhibitor (Xai) Reversal with Andexanet Alfa | Sarah Culbreth | ![]() |
![]() |
|||
PB-1089 | Pharmacokinetics of direct oral anticoagulants in overdose in self-poisoned patients admitted to the intensive care unit: a bi-center observational study | Virginie Siguret | ![]() |
![]() |
|||
PB-1090 | Differential Effects of Dabigatran, Rivaroxaban, Apixaban, Edoxaban and Betrixaban on Fibrinokinetics and their Modulation by FEIBA | Fakiha Siddiqui | ![]() |
![]() |
|||
PB-1092 | Response to New Oral Anticoagulants in Nigerian Patients with Venous Thromboembolism | Wuraola A. Shokunbi | ![]() |
![]() |
|||
PB-1093 | The Use of Direct Oral Anticoagulants in Inherited Antithrombin Deficiency | Andrew Doyle | ![]() |
![]() |
|||
PB-1094 | Therapy Persistence, Adherence and Predictors for Non-adherence in Patients who Switched from Vitamin K Antagonists to Direct Oral Anticoagulants | Myrthe M. A. Toorop | ![]() |
![]() |
|||
PB-1099 | Effectof Anticoagulant Treatment on Pain in Distal Deep Vein Thrombosis: An Ancillary Analysis from the CACTUS Trial | Marc Righini | ![]() |
![]() |
|||
PB-1101 | Automated IVC Filter Retrieval Requests and Haematology Liaison Improves Documentation and Retrieval of Temporary Inferior Vena Cava Filters: A Quality Improvement Initiative | Lara N. Roberts | ![]() |
![]() |
|||
PB-1102 | Mesoglycan vs Placebo in Secondary Prevention of Superficial Vein Thrombosis. Rationale and Protocol | Giuseppe Camporese | ![]() |
![]() |
|||
PB-1103 | Drug-drug Interactions of Direct Oral Anticoagulants in Clinical Settings: A Systematic Review | Ming Li | ![]() |
![]() |
|||
PB-1105 | An Audit of the Use of the Direct Oral Anticoagulants (DOACs) in Clinical Practice: 6 Years of Data | Sue Rhodes | ![]() |
![]() |
|||
PB-1107 | Clinical Predictors of Pulmonary Embolism for Inpatients: Are Computed Tomography Pulmonary Angiograms Being Requested Appropriately? Retrospective Analysis | Lisa Luo Lan Ling | ![]() |
![]() |
|||
PB-1109 | Anticoagulant Treatment Satisfaction and Concerns among Patients who Switched from Vitamin K Antagonists to Direct Oral Anticoagulants | Myrthe M.A. Toorop | ![]() |
![]() |
|||
PB-1110 | Superficial Vein Thrombosis (SVT) - treatment of SVT < 3cm from the deep vein with therapeutic DOAC - too close to call? | Marilyn Rees | ![]() |
![]() |
|||
PB-1111 | Recurrence Risk According to Anticoagulant Prescribed for the Secondary Prevention of Venous Thrombosis | Neil Zakai | ![]() |
![]() |
|||
PB-1112 | Efficacy and Safety of Apixaban for Treatment of Venous Thromboembolism in a Daily Practice-based Cohort | Stephan V. Hendriks | ![]() |
![]() |
|||
PB-1114 | Venous Thromboembolism in Asia and Worldwide: Emerging Insights from GARFIELD-VTE | Pantep Angchaisuksiri | ![]() |
![]() |
|||
PB-1115 | Low Level of Antithrombin Causes Underestimation of Anti-Xa and Discrepancy of Anti-Xa Test and Activate Partial Thromboplastin Time in the Monitoring of Heparin | Ari Ahn | ![]() |
![]() |
|||
PB-1116 | Outcomes in the secondary prevention of cerebral venous thrombosis in cancer only population | Cristhiam Rojas Hernandez | ![]() |
![]() |
|||
PB-1118 | Incidence and characteristics of venous thromboembolism in East Asian primary central nervous system lymphoma | Sung-Soo Yoon | ![]() |
![]() |
|||
PB-1120 | Extended anticoagulation for unprovoked venous thromboembolism: a survey on physicians´ considerations and guideline adherence | Maria Adriana de Winter | ![]() |
![]() |
|||
PB-1121 | MAC Project - Monitoring Anti-Coagulant therapy - Preliminary result from 2 years follow-up with Rivaroxaban users | Giuseppe Camporese | ![]() |
![]() |
|||
PB-1122 | Anticoagulant Treatment Patterns Among Venous Thrombosis Patients With Active Cancer: a Retrospective Analysis Using Four US Claims Databases | Daniel Wiederkehr | ![]() |
![]() |
|||
PB-1124 | Inferior vena cava filters in venous thromboembolism: indications, complications and extraction predictors | Fernando Chuliber | ![]() |
![]() |
|||
PB-1127 | A rock and a hard place - are we balancing bleeding and thrombotic risk in patients with thrombocytopenia? | Amanda Tey | ![]() |
![]() |
|||
PB-1128 | Retrospective study of the management of anticoagulant therapy in the pacemaker implant. Experience in an intensive care unit | Pablo Romero Garcia | ![]() |
![]() |
|||
PB-1129 | Superficial vein thrombosis: to treat beyond 3cm? | Marilyn Rees | ![]() |
![]() |
|||
PB-1131 | The use of apixaban or rivaroxaban in patients taking calcineurin inhibitors (CNIs): a review of therapeutic levels | Beverley J Hunt | ![]() |
![]() |
|||
PB-1135 | Therapeutic monitoring of Rivaroxaban plasma levels in 31 patients with or without major bleeding events (MBE) in a single centre in Singapore | Lester Jun Long Wong | ![]() |
![]() |
|||
PB-1136 | Prescribing practises of dabigatran in patients presenting with bleeding and requiring major surgery in a tertiary New Zealand Centre | Matt Wheeler | ![]() |
![]() |
|||
PB-1138 | Incidence and characteristics of double lumen induced central venous catheter-related thromboembolism in hemodialytic patients | Andree Kurniawan | ![]() |
![]() |
|||
PB-1139 | Evaluation of strategies focused on empowerment and change of behavior with a potential utility in patients with thromboembolic disorders | Luci Dusse | ![]() |
![]() |
|||
PB-1140 | Therapeutic monitoring of Apixaban levels in 17 patients in a single centre in Singapore | Christina Lai Lin Sum | ![]() |
![]() |
|||
PB-1141 | GMP Manufactured Ovine Mucosal Enoxaparin Is Comparable to Commercially Available Porcine Mucosal Enoxaparin | Manoj Niverthi | ![]() |
![]() |
|||
PB-1142 | Ovine Mucosal Enoxaparin Exhibit Comparable Pharmacokinetic Profiles to Porcine Mucosal Enoxaparin | Ahmed Kouta | ![]() |
![]() |
|||
PB-1143 | Vitamin K Antagonist vs Direct Oral AnticoagulantAs Anticoagulant Therapy in Patients with Inherited and Acquired Thrombophilia | Pável Olivera | ![]() |
![]() |
|||
PB-1147 | Intracardiac blood sampling reveals a better inhibition of hemostasis activation by dabigatran as compared to vitamin K antagonists during cryoballoon catheter ablation in atrial fibrillation | Zsuzsa Bagoly | ![]() |
![]() |
|||
PB-1149 | The Effect of Fasting Ramadan on the Efficacy and Safety of Oral Anticoagulants | Fakhr Alayoubi | ![]() |
![]() |
|||
PB-1151 | The Mortality Outcomes and Survival Patterns of Myeloproliferative Neoplasm Registry in Malaysia | Yee Yee Yap | ![]() |
![]() |
|||
PB-1157 | A Diabetic Microvascular Whole Blood Flow Model as a New Tool to Study Diabetes-Associated Thrombotic Complications | Verena Schroeder | ![]() |
![]() |
|||
PB-1158 | Frequency of Arterial Thromboembolism in Patients with Cancer: A Systematic Review | Allen Li | ![]() |
![]() |
|||
PB-1160 | Combination of high levels of fibrinogen and high sensitivity C-reactive protein enhances risk of acute coronary syndrome | Chananikan Makmool | ![]() |
![]() |
|||
PB-1164 | Endocan and homocysteine levels in Brazilian Renal Transplant Recipients | Luci Dusse | ![]() |
![]() |
|||
PB-1167 | Cardiovascular Diseases and Use of Antithrombotic Agents in Patients with End-stage Renal Disease on Hemodialysis: Cross-sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in HemoDIalysis Patients (VIVALDI) | Oliver Königsbrügge | ![]() |
![]() |
|||
PB-1171 | Thrombin generation and cardiovascular events in patients with peripheral arterial disease and patients with abdominal aortic aneurysm | Daniela Calderaro | ![]() |
![]() |
|||
PB-1174 | Experiences in Carotid Artery Dissection in Children | Patcharee Komvilaisak | ![]() |
![]() |
|||
PB-1175 | Audit of the Use of the GEKO Device on an Acute Stroke Unit (ASU) | Sue Rhodes | ![]() |
![]() |
|||
PB-1177 | Rheological and Hemostatic Aspects of Venous Thromboembolism in Patients with Severe Stroke | Kostiantyn Stepanchenko | ![]() |
![]() |
|||
PB-1179 | Performance of point-of care INR as part of pre-thrombolysis laboratory panel | Tuukka Helin | ![]() |
![]() |
|||
PB-1185 | Assessment of single-factor deficiency sensitivity of three APTT reagents | Claire Martin | ![]() |
![]() |
|||
PB-1187 | The Calibrated Automated Thrombinography for Hemophilia Treatment Monitoring | Natalya Silina | ![]() |
![]() |
|||
PB-1188 | Comparison of Factor VIII Half-life as Determined Using Two Web-accessible Population-based Pharmacokinetic Applications | Jerome Teitel | ![]() |
![]() |
|||
PB-1190 | Laboratory Measurement of Emicizumab Requires a Product Specific Calibrator | Helen Wilmot | ![]() |
![]() |
|||
PB-1191 | Thrombin-mediated Activation of Factor VIII is Insufficient to Produce All Necessary Cofactor Activity in vivo | Ivan Peyron | ![]() |
![]() |
|||
PB-1192 | The Traceability of Commercial Plasma Calibrators to the Plasma International Standard for Factor IX | Helen Wilmot | ![]() |
![]() |
|||
PB-1193 | Heterogeneity in levels of FVIII and VWF expression in subpopulations of human endothelial cells | David Lillicrap | ![]() |
![]() |
|||
PB-1195 | Recombinant FVIII-neutralising antibodies: characteristics and application in product testing and ex vivo models of haemophilia A | Carmen Coxon | ![]() |
![]() |
|||
PB-1196 | Paediatric factor VIII and IX reference intervals using STA®-ImmunoDef VIII and STA®-ImmunoDef IX | Natasha Letunica | ![]() |
![]() |
|||
PB-1199 | PBMCs from Healthy Individuals Respond Stronger and Differently towards FVIII than towards Myelin-oligodendrocyte Glycoprotein | Christoph Königs | ![]() |
![]() |
|||
PB-1200 | Relationship of Markers of Inflammation, Infection, and Endothelial Function to Mortality and Severity of Coagulopathy in Patients with Sepsis-associated DIC | Matthew Rondina | ![]() |
![]() |
|||
PB-1201 | Thrombin Time Test of Patients with Liver Disease Attending Medicine Outpatient Department UCTH, Calabar, Nigeria | Dorathy Chioma Okpokam | ![]() |
![]() |
|||
PB-1202 | Increased Platelet Contribution to Clot Strength in Cirrhotic Patients with Non-malignant Recent Portal Vein Thrombosis | Ecaterina Scarlatescu | ![]() |
![]() |
|||
PB-1207 | Intraperitoneal Activation of the Coagulation System via Tissue Factor-exposing Extracellular Vesicles and Enhanced Fibrinolysis in Patients with Advanced Chronic Liver Disease and Ascites | Johannes Thaler | ![]() |
![]() |
|||
PB-1208 | Evaluation of endothelial dysfunction and hypercoagulability markers in sickle cell anemia patients with and without hydroxyurea therapy | Bidossessi Wilfried Hounkpe | ![]() |
![]() |
|||
PB-1209 | Coagulation imbalance in patients with Acute-on-Chronic Liver Failure (ACLF) measured by global and classical coagulation tests | Elena Campello | ![]() |
![]() |
|||
PB-1212 | Increased Parameters of Thrombin Generation in Patients with Chronic Urticaria that Associate Angioedema | Alvaro Fernandez-Pardo | ![]() |
![]() |
|||
PB-1213 | A Novel Plasma Panel for the Assessment of Chronic Liver Disease Severity | Vladimir Bogdanov | ![]() |
![]() |
|||
PB-1214 | Efficiency of Anticoagulant Protein C System in Patients with Primary Myelofibrosis | Olesia Matvienko | ![]() |
![]() |
|||
PB-1221 | Endothelial Protein C Receptor (EPCR) Levels and EPCR Gene A3 Haplotype in Patients with Sickle Cell Anemia | Anil Tombak | ![]() |
![]() |
|||
PB-1225 | Clinical presentation and management of homozygous protein C deficiency:Case Study | Hatice Ilgen Sasmaz | ![]() |
![]() |
|||
PB-1226 | New, Highly Sensitive and Specific Multiplatform Latex Automated Turbidimetric Assay for Measurement of Free Protein S in Plasma | Claire Dunois | ![]() |
![]() |
|||
PB-1227 | Polymorphisms in Non-coding Regions of the Protein C Gene Regulate Plasmatic Protein C Levels | Alvaro Fernandez-Pardo | ![]() |
![]() |
|||
PB-1228 | Competitive Binding, and Accounting for Procoagulant Platelets, Significantly Change Thrombin Profiles in in vitro Coagulation | Mohan Anand | ![]() |
![]() |
|||
PB-1229 | New Functional Test for the TFPIa Cofactor Activity of Protein S Working in Synergy with FV-Short | Björn Dahlbäck | ![]() |
![]() |
|||
PB-1231 | Determining the Contribution of FXa Activation of FV to Thrombin Generation Using TIX-5: Variation in Healthy Controls and Association of High TIX-5 Sensitivity with Complications in Patients on Vitamin K Antagonists (VKAs) | Anja Maag | ![]() |
![]() |
|||
PB-1235 | A proximity-based in silico approach to identify redox-labile disulfide bonds: the example of FVIII | Carmen Coxon | ![]() |
![]() |
|||
PB-1240 | Heme induces expression and activation of hematopoietic tissue factor via TLR4 and PDIA3-dependent signaling pathways | Bidossessi Wilfried Hounkpe | ![]() |
![]() |
|||
PB-1245 | Longitudinal Evaluation of Plasma Circulating Microparticles and Serum Biomarker Levels in Women Destined to Develop Preeclampsia | Shrimati Shetty | ![]() |
![]() |
|||
PB-1246 | Investigation of Pharmacodynamic Biomarkers and Neutralizers for ONO-7684 (ONO-5450598), an Oral FXIa Inhibitor | Sho Kouyama | ![]() |
![]() |
|||
PB-1247 | Abstract 1: Assessment of Validated Risk Assessment Models and a Biomarker Ubiquitous in Routine Clinical Care to Identify Hospitalized Medical Patients at Risk for 90-day Post-discharge Venous Thromboembolism | Scott Woller | ![]() |
![]() |
|||
PB-1248 | Laboratory Marker of Hypercoagulability: A Ratio Combining Thrombin-generation with Fibrin-clot-Formation | Debora Bertaggia Calderara | ![]() |
![]() |
|||
PB-1249 | Antiphospholipid Antibodies and Thrombosis in BCR-ABL Negative Myeloproliferative Neoplasms | Rolandas Gerbutaviius | ![]() |
![]() |
|||
PB-1250 | Soluble P-selectin Level in Diagnosis of Deep Vein Thrombosis in Adult Myanmar Population | May Thandar Oo | ![]() |
![]() |
|||
PB-1252 | Effect of Standard and Intensive Insulin Therapy on Membrane-Bound Tissue Factor and Plasma Coagulation Biomarkers in Patients with Hyperglycemia and Acute Stroke: Differential Effects of rtPA Administration | A Koneti Rao | ![]() |
![]() |
|||
PB-1253 | Global Coagulation Assays in Transgender Individuals | Hui Yin Lim | ![]() |
![]() |
|||
PB-1256 | Absence of Measurable Contact System Activation of Coagulation during Hemodialysis: A Randomized Crossover Study | Christelle Orlando | ![]() |
![]() |
|||
PB-1257 | Potential Role of High-sensitive Troponin T in Identification of Patients with Pulmonary Embolism (PE) Who May Be Treated Safely at Home? | Stephan V. Hendriks | ![]() |
![]() |
|||
PB-1258 | Coagulation Activation in Sickle Cell Disease and the Effect of Hydroxyurea | Munira Borhany | ![]() |
![]() |
|||
PB-1260 | Global coagulation assays in patients with multiple myeloma and monoclonal gammopathy of unknown significance | Rowena Brook | ![]() |
![]() |
|||
PB-1261 | A new and rapid assay for intact fibrinogen adaptable to existing portable point-of-care devices | San Pun | ![]() |
![]() |
|||
PB-1262 | Mutational analysis and BAT scoring assessment in patients with Glanzmann´s Thrombasthenia | Kousar Perveen | ![]() |
![]() |
|||
PB-1265 | Abstract 2: Comparative Benefit of Adding a Biomarker Ubiquitously Available in Clinical Care to Validated Risk Assessment Models for the Identification of Hospitalized Medical Patients at Risk for 90-day Hospital-associated Venous Thromboembolism | Scott Stevens | ![]() |
![]() |
|||
PB-1266 | Age-adjusted D-dimer cutoff for the diagnosis of pulmonary embolism: a cost-effectiveness analysis | Marc Blondon | ![]() |
![]() |
|||
PB-1267 | Relationship of type 1 Plasminogen Activator Inhibitor with Glycosilated Hemoglobin levels in type 2 Diabetic Patients - Guillermo Almenara National Hospital - ESSALUD - Lima, 2016 | Haydee Iparraguirre | ![]() |
![]() |
|||
PB-1268 | Evaluation of hemostasis in patients with Alzheimer´s disease and frontotemporal dementia by thrombin generation test | Luci Dusse | ![]() |
![]() |
|||
PB-1269 | Thrombin generation test in Brazilian Renal Transplant Recipients | Luci Dusse | ![]() |
![]() |
|||
PB-1270 | Patterns of JAK2-V617F Testing and Predictive Value of Erythropoietin in Adult Erythrocytosis: Experience at a Comprehensive Cancer Center | Cristhiam Rojas Hernandez | ![]() |
![]() |
|||
PB-1274 | Plasma fibrin clot proteomics in healthy subjects: relation to clot permeability and lysis time | Anetta Undas | ![]() |
![]() |
|||
PB-1275 | No change in coagulation factor levels after knee arthroscopy | Carolina Eveline Touw | ![]() |
![]() |
|||
PB-1276 | Integrated GWAS and Gene Expression Data Identifies ORM1 as Potential Regulator of Plasma Cell-free DNA Levels in Families of the GAIT2 Project | Jose Manuel Soria | ![]() |
![]() |
|||
PB-1277 | Effects of veno-venous extracorporeal membrane oxygenation on coagulation factors- a prospective observational study | Deepa Jayakody Arachchillage | ![]() |
![]() |
|||
PB-1278 | Thrombin generation in patients with lower-leg trauma or knee arthroscopy | Carolina Touw | ![]() |
![]() |
|||
PB-1279 | Definitions, adjudication, and reporting of pulmonary embolism-related death in clinical studies: a systematic review | Noémie Kraaijpoel | ![]() |
![]() |
|||
PB-1280 | Diagnostic accuracy of four different D-dimer assays Additional analyses of the YEARS study | Roisin Bavalia | ![]() |
![]() |
|||
PB-1281 | Evaluation of thrombin generation in patients with dermatomyositis and polymyositis | Jerzy Dropinski | ![]() |
![]() |
|||
PB-1283 | Factors Associated with a Negative D-dimer Test in Patients Diagnosed with Acute Symptomatic Pulmonary Embolism | Stefano Barco | ![]() |
![]() |
|||
PB-1284 | The FDP/D-dimer ratio and LDH/Hb ratio are useful to distinguish between TTP and DIC | Nobushiro Nishimura | ![]() |
![]() |
|||
PB-1286 | Validation of a Profile of 4 Plasmatic Metabolites Associated with Venous Thromboembolism | Álvaro Fernández-Pardo | ![]() |
![]() |
|||
PB-1287 | Specific Protein Plasma Profile Associated to Venous Thromboembolism | Alvaro Fernandez-Pardo | ![]() |
![]() |
|||
PB-1289 | Thrombin Generation in Patients Undergoing Pharmacokinetics Analysis | Nikoleta Daskoulidou | ![]() |
![]() |
|||
PB-1291 | Serum Lipoprotein (a) Is Not Increased in Patients with Previous Spontaneous Venous Thrombosis or Correlated with Global Fibrinolysis | Andreza Lamônica | ![]() |
![]() |
|||
PB-1292 | TEG-based Evaluation of Gender-associated Hypercoagulability | Kristen Carter | ![]() |
![]() |
|||
PB-1293 | Thrombin Generation and Endothelial Dysfunction in Patients with Systemic Sclerosis | Jerzy Dropinski | ![]() |
![]() |
|||
PB-1294 | Assessment of Factor IX Padua Activity with a One-stage Clotting Method and with FXIa- and Tissue Factor/FVIIa-based Chromogenic Methods | Steffen Rosén | ![]() |
![]() |
|||
PB-1295 | Recombinant Factor IX Fused with Albumin (rFIX-HSA) is Underassigned by One-stage Methods with Silica as Contact Activator | Steffen Rosén | ![]() |
![]() |
|||
PB-1296 | Factor VIII, IX and XI measurement by one stage clotting assay with Silica Clotting Time Confirm reagent: A clinical laboratory helpful tool in the presence of lupus anticoagulant | Marina Lopez | ![]() |
![]() |
|||
PB-1297 | Analytical Performance of a Modified One-Stage Clotting Assay for Measuring Emicizumab on cobas t 511/711 Analyzers | Nina Richter | ![]() |
![]() |
|||
PB-1304 | Next Generation Sequencing as a New Tool to Improve Molecular Diagnosis of VWD | Christophe Zawadzki | ![]() |
![]() |
|||
PB-1307 | Discrepancy between clotting versus chromogenic FVIII procoagulant assay is determined by a combination of APTT reagent and FVIII-deficient plasma | Atsuo Suzuki | ![]() |
![]() |
|||
PB-1312 | Assays performed on samples containing emicizumab - data from a multicentre study of UK NEQAS Blood Coagulation (BC) laboratories | Ian Jennings | ![]() |
![]() |
|||
PB-1316 | Correlation of Bleeding Scores with Flowcytometry Platelet Aggregation Test in Patients with a Suspected Bleeding Disorder | Jasmina Ahluwalia | ![]() |
![]() |
|||
PB-1317 | Exome Sequence Findings and Bleeding Manifestations for Uncharacterized Platelet Function Disorders with Impaired Aggregation Responses and/or Non-syndromic Dense Granule Deficiency: Results from the Hamilton Platelet Disorder Study | Catherine Hayward | ![]() |
![]() |
|||
PB-1318 | Microscopic Platelet Adhesion Assessment - An Approach towards Standardization | Johanna Charlotte Clauser | ![]() |
![]() |
|||
PB-1322 | Standardization of Light Transmission Aggregometry for the diagnosis of inherited platelet function disorders: First inter-laboratory external quality assessment in Germany and Austria | Karina Althaus | ![]() |
![]() |
|||
PB-1324 | Sensitive method for diagnosing a platelet population behavior after stimulation | Alena Litvinenko | ![]() |
![]() |
|||
PB-1327 | Comparison between Plateletworks Method and Aggregation with Platelet-rich Plasma for the Evaluation of Platelet Function in Patients with Acute Coronary Syndrome | Emanuel Sueldo | ![]() |
![]() |
|||
PB-1328 | The Total Thrombus Formation (T-TAS) Platelet Assay, a Novel Point-of-Care Test that Uses Arterial Shear Stress Evaluating Antiplatelet Therapy | K.L. Zheng | ![]() |
![]() |
|||
PB-1329 | The Effect of Rivaroxaban on the Platelet Functional Activity | Olesya Matvienko | ![]() |
![]() |
|||
PB-1331 | First Evidence: Reduced Thrombin-dependent Platelet Aggregation by Selected Xabans | Lubica Vadelova | ![]() |
![]() |
|||
PB-1333 | Plasminogen Activator Inhibitor-1 Deficiency Prevents the Neonatal Chronic Lung Disease in Mice | Kohei Tatsumi | ![]() |
![]() |
|||
PB-1337 | Inhibition of the Procarboxypeptidase U (proCPU, TAFI, proCPB2) System due to Hemolysis | Joachim Mertens | ![]() |
![]() |
|||
PB-1340 | Fibrinolysis Patterns of Different Plasminogen Mutant Proteins in Patients with Inherited Plasminogen Deficiency: Impact on the Development of Ligneous Conjunctivitis | Nadine Ajzenberg | ![]() |
![]() |
|||
PB-1341 | Dipicolinic Acid Release t-PA from HUVEC | Hiroyuki Sumi | ![]() |
![]() |
|||
PB-1342 | Fibrin Clots Containing NETs Show Slower Fibrinolysis and Are Stiffer in Patients with Diabetes | Judith Juliana de Vries | ![]() |
![]() |
|||
PB-1343 | Fibrin clot lysis analysis; tissue factor versus thrombin as activator | Mai Stenulm Veirup | ![]() |
![]() |
|||
PB-1344 | Exploratory study of fibrinolytic parameters in patients with JAK2V617F positive essential thrombocythemia | Sithakom Phusanti | ![]() |
![]() |
|||
PB-1345 | Fibrinogenolytic effects of Night Adder snake venoms | Francisco Cyrne Pacheco Coimbra | ![]() |
![]() |
|||
PB-1350 | Interaction of Cationic and Anionic of Polyamidoamine Dendrimers with Plasminogen: Influence on the Structure and Activation of Zymogen by Streptokinase | Liliya Mukhametova | ![]() |
![]() |
|||
PB-1352 | Gender-specific alteration in a2-antiplasmin incorporation in type 2 diabetes mellitus | Agata Hanna Bryk | ![]() |
![]() |
|||
PB-1353 | Highest Nattokinase Activity in Japanese Fermented Food-Natto | Hiroyuki Sumi | ![]() |
![]() |
|||
PB-1354 | Determinants of plasma fibrin clot lysis using three different assays in patients with aortic stenosis | Jakub Siudut | ![]() |
![]() |
|||
PB-1356 | Elucidation of the Molecular Mechanisms of Nanobodies that Affect Plasminogen Activator Inhibitor 1 (PAI-1) Activity Highlights their Versatility in Modulating Various Stages in the PAI-1/Plasminogen Activator (PA) Interaction | Paul J. Declerck | ![]() |
![]() |
|||
PB-1358 | Single institution experience of thrombolysis for acute pulmonary embolism in a retrospective cohort of Australian patients | Ming Sheng Lim | ![]() |
![]() |
|||
PB-1359 | A new treatment for thrombosis prevention? | Niklas Bergh | ![]() |
![]() |
|||
PB-1361 | Indications and Outcomes of Thrombolytic Therapy 2010-2016: A Retrospective Single Center Study | Peter Verhamme | ![]() |
![]() |
|||
PB-1370 | Acquired FXIII inhibitor: patient characteristics and treatment outcome, a case series | Sheng-Chieh Chou | ![]() |
![]() |
|||
PB-1371 | Venous Thromboembolism Trends and Impact in Patients with Cirrhosis: Analysis of The National Inpatient Sample Database 2003-2014 | Ian Greenberg | ![]() |
![]() |
|||
PB-1373 | Influence of antiagregation therapy in bone marrow biopsy heamorrhagic complication | Rogerio Pastore Bassitt | ![]() |
![]() |
|||
PB-1374 | Acquired Hemophilia A (AHA) : A Single Centre Malaysian Outlook | Christopher, Chin Keong Liam | ![]() |
![]() |
|||
PB-1378 | Acquired von Willebrand Syndrome: A Case Series in a University Hospital in Argentina | Maximiliano Villagra Iturre | ![]() |
![]() |
|||
PB-1379 | Acquired VKOR Inhibitor: A New Entity? | Veena Selvaratnam | ![]() |
![]() |
|||
PB-1380 | The Paradox: Bleeding Presentation in Antiphospholipid Syndrome | Veena Selvaratnam | ![]() |
![]() |
|||
PB-1381 | Use of a thrombin generation assay and thromboelastometry in the assessment of the efficacy of treatment with activated prothrombin complex concentrate (APCC) or recombinant Factor VIIa (rFVIIa) concentrate in patients with acquired haemophilia and in pat | Krystyna Zawilska | ![]() |
![]() |
|||
PB-1382 | Acquired Hemophilia A Presenting in a 13 Year-old Boy - A Clinical Case | Rute Preto | ![]() |
![]() |
|||
PB-1383 | BLEEDING COMPLICATIONS AFTER PERCUTANEOUS RENAL BIOPSY: Analysis of probable risk factors | Veronica Privitera | ![]() |
![]() |
|||
PB-1384 | Combination of cyclophosphamide and corticosteroids therapy facilitate remission in acquired hemophilia A patients with high titers of inhibitors: A single center experience in China | Naifang Ye | ![]() |
![]() |
|||
PB-1386 | Three successful cases of AHA patients presenting severe cardiovascular diseases treated with susoctocog-alfa (rpFVIII): a single centre experience | Ezio Zanon | ![]() |
![]() |
|||
PB-1388 | Acquired Hemophilia A Presenting in an Elderly Man after a Thrombotic Event - A Clinical Case | Rute Preto | ![]() |
![]() |
|||
PB-1389 | Acquired Hemophilia A and B Associated with Thyroid Cancer Successfully Treated by Activated Factor VII (rFVIIa). Case Report | Alejandro Jaramillo Yepes | ![]() |
![]() |
|||
PB-1390 | Properdin, a positive regulator of the alternative pathway of complement, inhibits factor XI autoactivation by dextran sulphate | Samantha Heal | ![]() |
![]() |
|||
PB-1391 | The Evaluation of Paroxismal Nocturnal Hemoglobinuria Patients who Underwent Eculizumab Therapy | Fahri Sahin | ![]() |
![]() |
|||
PB-1392 | Reported Presentation, Treatment, Mutation Analysis and Outcome of Two Children with Atypical Hemolytic Uremic Syndrome | Pongpak Pongphitcha | ![]() |
![]() |
|||
PB-1395 | Evaluation of fulfilment sequences of two different criteria for assessing coagulopathy in sepsis: a nationwide Japanese registry study | Katsunori Mochizuki | ![]() |
![]() |
|||
PB-1396 | Predictive value of soluble fibrin and new diagnostic criteria by the Japanese Society on Thrombosis and Hemostasis (JSTH) for the prognosis of patients with sepsis-associated disseminated intravascular coagulation | Seiji Madoiwa | ![]() |
![]() |
|||
PB-1397 | A Study of the Prognostic Value of Smartphone Application on Disseminated Intravascular Coagulation (DIC) Score in Prediction of 28-day Mortality | Tanapun Thamgrang | ![]() |
![]() |
|||
PB-1399 | Use of rFIX-FP in a child with mild hemophilia B during a surgical procedure | John Puetz | ![]() |
![]() |
|||
PB-1400 | Psychosocial Issues in Mothers of Children with Hemophilia | Aya Nakao | ![]() |
![]() |
|||
PB-1401 | Long-term Safety of N8-GP (turoctocog alfa pegol) Prophylaxis in Patients with Severe Haemophilia A | Nicola J Curry | ![]() |
![]() |
|||
PB-1405 | Successful Management with a Major Trauma Caused by Vehicle Accident in a Severe Hemophilia A Patient with Inhibitor under Emicizumab Treatment | Sheng-Chieh Chou | ![]() |
![]() |
|||
PB-1407 | Menorrhagia in Congenital Factor Deficiencies | Zafer Salcioglu | ![]() |
![]() |
|||
PB-1409 | Evaluation of the Analytical Performances of a New Emicizumab Assay on STA-R & STA Compact Max | Matthieu Bourdin | ![]() |
![]() |
|||
PB-1412 | Validation of the Patient Reported Outcomes Burdens and Experiences (PROBE) Study Questionnaire | Mark Skinner | ![]() |
![]() |
|||
PB-1413 | Evaluation of Active Genetic Counseling Service for Female Family Members of Hemophilia Patients in Korea | Hyon Kim | ![]() |
![]() |
|||
PB-1414 | Identification of New Deep Intronic Variants Causing Hemophilia A by Whole F8 Gene Sequencing, mRNA Analysis and Functional Confirmation, in "Variant-Negative" French and Canadian Patients | Fanny Lassalle | ![]() |
![]() |
|||
PB-1415 | Measuring Health Related Quality of Life (HRQoL) in Boys with Hemophilia Using Extended Half-life Clotting Factor Concentrates (CFCs) | saunya dover | ![]() |
![]() |
|||
PB-1417 | The Outcome of Intermediate-dose Prophylaxis and On-demand Episodic Treatment for Severe Hemophilia A Patients in Taiwan - A Longitudinal Study | Shyh-Shin Chiou | ![]() |
![]() |
|||
PB-1422 | Simoctocog-alfa (rhFVIII): an interesting option for the Immune Tolerance Induction Rescue (ITI-R) in the hemophilia A patients with high-titer inhibitors | Ezio Zanon | ![]() |
![]() |
|||
PB-1423 | Results from the Immune Tolerance Induction (ITI) with moroctocog-alpha in a population of haemophilia A patients and high-titre inhibitors: the REF.IT Registry | Ezio Zanon | ![]() |
![]() |
|||
PB-1424 | Comparison of Pharmacokinetic Outputs from a Non-compartmental Analysis and myPKFiT™ in Taiwanese Hemophilia Patients | Shin-Nan Cheng | ![]() |
![]() |
|||
PB-1425 | Survey of Haemophilia Care in Nigeria: Physicians response from 35 centres in 20 states of the Federation | Wuraola A. Shokunbi | ![]() |
![]() |
|||
PB-1428 | Clinical Use of Recombinant Factor VIII Fc (rFVIII-Fc) in Patients with Haemophilia A in a Single Centre | Segolene Claeyssens | ![]() |
![]() |
|||
PB-1429 | The Estimated Impact of New Therapies on Factor VIII (FVIII) Use and Product Cost by 2023 | Jonathan Ducore | ![]() |
![]() |
|||
PB-1431 | Various complications after vascular procedure in patients with hemophilia | Eun Jin Choi | ![]() |
![]() |
|||
PB-1433 | Low-dose immune tolerance induction strategy eradicates high-titer inhibitor with poor risk(s) in hemophilia A children: a pilot study in China | Zekun Li | ![]() |
![]() |
|||
PB-1435 | Review of a Port-A-Cath Training Programme for Caregivers in a Paediatric Haemophilia Treatment Centre | Chiew Ying Lim | ![]() |
![]() |
|||
PB-1436 | Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa) in Spain | Santiago Bonanad | ![]() |
![]() |
|||
PB-1437 | Management and Outcomes of Hemophilia Carriers during Pregnancy and Peripartum Period: A Hemophilia Treatment Center Experience | Hana Iris Lim | ![]() |
![]() |
|||
PB-1442 | Transition from Standard Half-life to Extended Half-life Products in Patients with Haemophilia A and B: A Single Center Experience | Marissa Johanna Maria Traets | ![]() |
![]() |
|||
PB-1444 | Seroprevalence and Clinical Characteristics of Viral Hepatitis in Hemophilia Patients | Fahri Sahin | ![]() |
![]() |
|||
PB-1451 | Prediction of anti-FVIII inhibitor persistence by anti-FVIII IgG subclasses in patients with severe hemophilia a in the SIPPET cohort study | Roberta Palla | ![]() |
![]() |
|||
PB-1457 | Results from a Prospective, Multicenter, Dose Escalating, Prophylaxis Study in Young Boys with Severe Haemophilia A in China: The China Haemophilia Individualized Prophylaxis Study (CHIPS) (NCT02999308) | YUAN LI | ![]() |
![]() |
|||
PB-1458 | Social Participation of Patients with Haemophilia: Preliminary Results from the Nationwide ´Haemophilia in the Netherlands 6 study´ | Erna van Balen | ![]() |
![]() |
|||
PB-1460 | Comparative Pharmacokinetic Study between Alphanate and Octanate Using WAPPS-Hemo | Santiago Bonanad | ![]() |
![]() |
|||
PB-1461 | Clinical Assessment with Focus on Health-related Quality of Life in Adult Patients with Severe Hemophilia B | Anna Buczma | ![]() |
![]() |
|||
PB-1462 | Acquired Haemophilia Still Remains a Complex Clinical Challenge | Cristina Claudia Tărniceriu | ![]() |
![]() |
|||
PB-1463 | 6 Consecutive Patients and 100% of Inhibitors: Is Inhibitor Development Inevitable? | Cristina Catarino | ![]() |
![]() |
|||
PB-1464 | Utility of an Educational Material for Primary Caregivers of Pediatric Patients with Hemophilia | Aida Mashenka Moreno González | ![]() |
![]() |
|||
PB-1465 | A Case Series of Continuous Infusion with Kovaltry® (Octocog Alfa) in Patients with Hemophilia A | Jerome Teitel | ![]() |
![]() |
|||
PB-1468 | Comorbidity and transfusion transmitted infections in patients with severe haemophilia: Report from Taiwan Society of Thrombosis and Hemostasis registry | Jiaan-Der Wang | ![]() |
![]() |
|||
PB-1469 | Structure, mechanical and lytic stability of fibrin and plasma coagulum generated by staphylocoagulase from Staphylococcus aureus | Craig Thelwell | ![]() |
![]() |
|||
PB-1472 | Systemic Antifibrinolytic Agents for Hemoptysis Management in Adults with Cystic Fibrosis | Jean Connors | ![]() |
![]() |
|||
PB-1473 | Heparin-binding Copolymer as a Universal Antidote for Low-molecular-Weight Heparins in Rats | Bartłomiej Kalaska | ![]() |
![]() |
|||
PB-1474 | Cerebral Hemorrhage Developed in a Hemophilia A Patient without Inhibitor during Prophylactic Treatment with Emicizumab | Azusa Nagao | ![]() |
![]() |
|||
PB-1475 | Barriers and Challenges for the Fast Treatment of Bleeds in the Non-haemophilia Treatment Centre Hospital Setting | Robert Klamroth | ![]() |
![]() |
|||
PB-1476 | Reversal of Anticoagulation in Patients on Rivaroxaban or Apixaban (DOAC) with Major Bleeding Episodes (MBE) with 4 Factor Prothrombin Complex Concentrates (PCC): A Multicentre Retrospective Study | Christian Aledia Gallardo | ![]() |
![]() |
|||
PB-1478 | Injectable Biotinylated Platelets for Transfusion in Clinical Trials | Arnaud Dupuis | ![]() |
![]() |
|||
PB-1479 | Thromboelastometry in patients with positive lupus anticoagulant. Is there any potential impact on haemostasis monitoring during Cardiovascular Surgery? | Marina Sol Lopez | ![]() |
![]() |
|||
PB-1480 | Dynamic coagulability during cardiovascular surgery and its correlations with bleeding volume | Satoshi Fujii | ![]() |
![]() |
|||
PB-1481 | Real-world use of 4-factor prothrombin complex concentrates (4F-PCC) in warfarin-associated intracranial haemorrhage patients in Hong Kong: a descriptive patient management protocol | Wing Chi Fong | ![]() |
![]() |
|||
PB-1482 | Management of Antithrombotic Therapy After Gastrointestinal Bleeding: A Qualitative Study of Healthcare Providers | Deborah Siegal | ![]() |
![]() |
|||
PB-1483 | Perioperative Management of Antiplatelets and Anticoagulants in Elective Surgery | James Sindone | ![]() |
![]() |
|||
PB-1485 | Seek and Ye Shall Find - Elearning as a Method to Improve Knowledge of Bleeding Management | Louise English | ![]() |
![]() |
|||
PB-1487 | Efficacy of Three Factor Prothrombin Complex in Achieving Haemostasis in Patients with Major Bleeding on Anti-Coagulation - Retrospective Single Centre Study | Usha Chandra Sekaran | ![]() |
![]() |
|||
PB-1488 | GPVI shedding contributes to platelet dysfunction in trauma-induced coagulopathy | Samantha Montague | ![]() |
![]() |
|||
PB-1489 | Efficacy and safety of a 4-factor prothrombin complex concentrate for management of direct Xa inhibitor-induced major bleeding | Paul Dobesh | ![]() |
![]() |
|||
PB-1491 | A Comparison of Management Strategies for Patients with Warfarin-induced Bleeding | Paul Dobesh | ![]() |
![]() |
|||
PB-1492 | Warfarin Reversal with a 4-factor Prothrombin Complex Concentrate Prior to Urgent surgery | Paul Dobesh | ![]() |
![]() |
|||
PB-1493 | Direct Xa-inhibitor Reversal with a 4-factor Prothrombin Complex Concentrate Prior to Urgent Surgery | Paul Dobesh | ![]() |
![]() |
|||
PB-1494 | Comparative Studies on the Anticoagulant Activities of Orally Active Anti-Xa and Anti-IIa Agents in Whole Blood and Retrieved Plasma and their Neutralization by FEIBA | Rithik Raina | ![]() |
![]() |
|||
PB-1495 | Idarucizumab for Dabigatran Reversal in Clinical Practice: A French Retrospective Study of 41 Cases | Nicolas Gendron | ![]() |
![]() |
|||
PB-1496 | von Willebrand Factor in Experimental Malaria-associated Acute Respiratory Distress Syndrome | Sirima Kraisin | ![]() |
![]() |
|||
PB-1497 | Involvement of Glycoprotein VI in Platelet Mediated Amyloid-ß Fibril Formation | Lili Donner | ![]() |
![]() |
|||
PB-1498 | Regulation of NET formation by von Willebrand factor | Kimberly Martinod | ![]() |
![]() |
|||
PB-1503 | Partially Methylated Domains of Fetal and Adult Liver Sinusoidal Endothelial Cells Revealed Cell-type as Well as Differentiation-stage Specificity | Muhammad Ahmer Jamil | ![]() |
![]() |
|||
PB-1506 | Decreased Thrombin Generation Potential is Associated with Increased Thrombin Generation Markers in Sepsis Associated Coagulopathy | Fakiha Siddiqui | ![]() |
![]() |
|||
PB-1507 | Plasma Activated Protein C Activity in the Presence of Recombinant Thrombomodulin in vivo and in vitro | Takashi Ito | ![]() |
![]() |
|||
PB-1508 | Platelet aggregation in patients with septic shock | Mathies Appel Laursen | ![]() |
![]() |
|||
PB-1509 | Investigating the role of tissue factor in abdominal sepsis | Agostina Carestia | ![]() |
![]() |
|||
PB-1511 | HIGH PLASMATIC LEVELS OF CELL FREE DNA ARE ASSOCIATED WITH POOR PROGNOSIS IN SEPTIC PATIENTS | Mauro Hernán Moiana | ![]() |
![]() |
|||
PB-1513 | Activation-specific small binding proteins targeted towards the integrin Mac-1 - Measuring inflammation by means of monocyte activation in STEMI- and ECMO-patients | Patrick Malcolm Siegel | ![]() |
![]() |
|||
PB-1514 | Platelets and coagulation mediate bacterial adhesion to damaged and inflamed heart valves in Staphylococcus aureus endocarditis | Severien Meyers | ![]() |
![]() |
|||
PB-1515 | Coagulation and fibrinolysis waveform analysis may identify the patients susceptible for multiple organ failure and thrombocytopenia in septic DIC | Noritaka Yada | ![]() |
![]() |
|||
PB-1516 | Pro-inflammatory Macrophage Polarization enhances Neutrophil Extracellular Trap Degradation | Patrick Haider | ![]() |
![]() |
|||
PB-1517 | Investigating the role of neutrophils and NETs in Staphylococcus aureus endocarditis | Severien Meyers | ![]() |
![]() |
|||
PB-1518 | Remote Ischemic Preconditioning Does Not Influence Lectin Pathway Protein Levels in Cancer Patients Undergoing Surgery: A Randomized Controlled Trial | Kristine Frederiksen | ![]() |
![]() |
|||
PB-1521 | MiR-146a participates in thrombo-inflammation regulating neutrophil extracellular trap formation | Ana Belen Arroyo Rodriguez | ![]() |
![]() |
|||
PB-1523 | Developing a Novel Stem Cell and Gene Therapy System Based on Resveratrol-induced HSP70 Promoter-regulated VEGFA Expression | Kowit-Yu Chong | ![]() |
![]() |
|||
PB-1524 | Prolonged Therapeutic Effects of Adipose-derived Stem Cells via the Photoactivation after Ischemic Injury | Jianbo Wu | ![]() |
![]() |
|||
PB-1526 | Symptomatic Profiles of Chinese Patients with Essential Thrombocythemia Assessed by MPN 10 Score | Ting Sun | ![]() |
![]() |
|||
PB-1527 | miR-125a-5p Regulates Human and Mouse Thrombopoiesis through Leukocyte Cytosolic Protein 1 (LCP1) | Paul F. Bray | ![]() |
![]() |
|||
PB-1529 | Buffy coat, a potential source of hematopoietic stem cells for in vitro platelet production | Irene Marini | ![]() |
![]() |
|||
PB-1530 | Aerobic Glycolysis and the Consequent Flux through Pentose Phosphate Pathway Fuel Platelet Activation: Small-molecule Modulators of Platelet Metabolism as Anti-thrombotic Agents | Paresh Kulkarni | ![]() |
![]() |
|||
PB-1531 | The Highly Efficacious Antithrombotics Act as Selective Inhibitors of aIIbß3 Outside-in Signaling with a High Safety Profile | Tur-Fu Huang | ![]() |
![]() |
|||
PB-1532 | A Proposed "ABN Score" for Prediction of Aspirin Resistance in Thai Patients with Polycythemia Vera and Essential Thrombocythemia | Yingyong Chinthammitr | ![]() |
![]() |
|||
PB-1533 | Do paracetamol and nonsteroidal anti-inflammatory drugs affect the quality of platelets for transfusion? | Dianne E. Van Der Wal | ![]() |
![]() |
|||
PB-1534 | APAC, a dual antiplatelet and anticoagulant - towards a local, vascular targeting antithrombotic | Riitta Lassila | ![]() |
![]() |
|||
PB-1535 | Outside-in Integrin Signaling Induces Disabled-2 (Dab2) Ser24 Phosphorylation Causing Dab2 Dissociation from Phosphatidic Acid in Human Platelets | Hui-Ju Tsai | ![]() |
![]() |
|||
PB-1536 | Plasma Inhibitors of Platelet Sheddase Activity - Rocks to the Scissors on the Paper | Christine Lee | ![]() |
![]() |
|||
PB-1538 | All-trans retinoic acid (ATRA) impairs platelet function and thrombus formation and inhibits protein kinase C ßI and d phosphorylation | Jianlin Qiao | ![]() |
![]() |
|||
PB-1539 | The mammalian target of rapamycin controls platelet integrin activation, aggregation, and ischemic stroke | Robert Campbell | ![]() |
![]() |
|||
PB-1540 | Lenalidomide and dexamethasone enhanced platelet activation and in vitro thrombus formation under arterial flow | Fehaid Alanazi | ![]() |
![]() |
|||
PB-1542 | The role of the formin proteins mDia1 and Fhod1 on megakaryocyte and platelet function | Steve Thomas | ![]() |
![]() |
|||
PB-1543 | Platelet function testing by flow cytometry in venous and arterial blood: A comparative study | Sofia Ramstrom | ![]() |
![]() |
|||
PB-1546 | Moderate decreased platelet counts but high platelet activation defects alter hemostasis and arterial thrombosis after partial hepatectomy in mice | Lili Donner | ![]() |
![]() |
|||
PB-1549 | The rate of platelet activation varies within the normal population and does not correlate with maximal levels of platelet activation | Joanne Mitchell | ![]() |
![]() |
|||
PB-1550 | Assessment of Platelet Function after Shear Stress Simulation Using ex vivo Closed-loop ECC Model (Modified Chandler-loop) | Jan Zlamal | ![]() |
![]() |
|||
PB-1552 | The integrin aIIbß3 signalling pathway is hyperactivated in platelets from obese patients: a phosphoproteomic study | Maria N. Barrachina | ![]() |
![]() |
|||
PB-1554 | Comparison of Anucleated and Nucleated Platelet Transcriptomes | Andrew D. Johnson | ![]() |
![]() |
|||
PB-1555 | Gradient dependent inhibition of platelet stimulatory G-Protein coupled receptors is mediated through cAMP dependent pathway | Ankit S Macwan | ![]() |
![]() |
|||
PB-1556 | Potential for ice recrystallisation inhibitors to improve cryopreserved platelet recovery and quality | Lauren Waters | ![]() |
![]() |
|||
PB-1557 | The role of NMDA receptors in platelet specific hemostasis | Lili Donner | ![]() |
![]() |
|||
PB-1558 | Elevated Soluble GPVI Levels in Patients with Symptomatic Aortic Stenosis and Left Ventricular Remodelling | Cecile Oury | ![]() |
![]() |
|||
PB-1559 | Panax Notoginseng Flower Extratives and Its Saponins Attenuate Human Platelet Hyperactivity via P2Y12 Signaling Pathways in vitro | Yan Yang | ![]() |
![]() |
|||
PB-1560 | Reelin Modulates Glycoprotein VI and Integrin Outside-in Signaling of Platelets | Meike Klier | ![]() |
![]() |
|||
PB-1561 | Src-family kinase inhibition by dasatinib blocks both initial and subsequent platelet deposition on collagen under flow, but lacks any effect when thrombin is generated | Scott Diamond | ![]() |
![]() |
|||
PB-1563 | Platelets express a truncated form of TrkB involved in BDNF signaling | Imane Boukhatem | ![]() |
![]() |
|||
PB-1566 | Phosphate-induced ORAI1 expression and store operated Ca2+ entry in megakaryocytes | Tamam Bakchoul | ![]() |
![]() |
|||
PB-1569 | Study of Calcium Signaling Dynamics in Single Platelets | Daria Spiryova | ![]() |
![]() |
|||
PB-1572 | Combining a novel GPVI inhibitor ACT017 with conventional antiplatelet therapy provides greater inhibition of platelet-leukocyte aggregate formation | Mark Thomas | ![]() |
![]() |
|||
PB-1573 | Ceruloplasmin reduces the ability of thrombin to cause platelet aggregation | Daria Grigorieva | ![]() |
![]() |
|||
PB-1574 | Effect of monomeric myeloperoxidase on platelet function | Irina Gorudko | ![]() |
![]() |
|||
PB-1577 | Multiplex profiling of Platelet Rich Plasma vs Platelet Concentrate bioproducts: A comparative analysis | Laura Gutierrez | ![]() |
![]() |
|||
PB-1579 | "TWO-FACED TTP" - The Many Causes of Thrombotic Microangiopathy in Cancer Patients | Rebecca Barrett | ![]() |
![]() |
|||
PB-1581 | Adult Onset Hereditary Thrombotic Thrombocytopenic Purpura (TTP) with a Novel ADAMTS13 Mutation | Julian Matias Freue | ![]() |
![]() |
|||
PB-1584 | Clinical Safety Of Therapeutic Plasma Exchange with Fresh Frozen Plasma Inactivated with Mirasol PRT System in Patients with Acquired TTP | Magdalena Letowska | ![]() |
![]() |
|||
PB-1590 | Evaluation of A Rapid, Fully-automated ADAMTS13 Activity Assay | Josep Serra | ![]() |
![]() |
|||
PB-1594 | The presence of anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura patients does not hamper correct determination of ADAMTS13 antigen levels | Charlotte Dekimpe | ![]() |
![]() |
|||
PB-1595 | A NOVEL MUTATION DESCRIPTION IN LATE-ONSET PHENOTYPE CASE OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) | Juvenal Paiva | ![]() |
![]() |
|||
PB-1596 | ADAMTS13 antigen together to collagen binding to von Willebrand factor (VWF:CB) and VWF antigen (VWF:Ag) were potential markers of acute disease severity in acquired thrombotic thrombocytopenic purpura (aTTP) | Juvenal Paiva | ![]() |
![]() |
|||
PB-1597 | Severe hemolytic jaundice with thrombocytopenia at birth in congenital TTP is caused by physiological constriction of ductus arteriosus | Kazuya Sakai | ![]() |
![]() |
|||
PB-1598 | Non-severe Congenital Deficiency of ADAMTS13 Presenting as Thrombotic Microangiopathy during Pregnancy | Miguel Escobar | ![]() |
![]() |
|||
PB-1599 | Complement Abnormalities in a Cohort of Argentinean Patients with Atypical Hemolytic Uremic Syndrome | Célia Dos Santos | ![]() |
![]() |
|||
PB-1604 | The Incidence of Low ADAMTS13 Activity in Systemic Lupus Erythematosus Patients with Thrombocytopenia | Theera Ruchutrakool | ![]() |
![]() |
|||
PB-1605 | Rituximab prophylaxis in acquired Thrombotic Thrombocytopenic Purpura improves thrombus formation by shear flow-based assay | Marie Scully | ![]() |
![]() |
|||
PB-1606 | A Survey on the use of rituximab in Korean patients with acquired thrombotic thrombocytopenic purpura | Sung-Hyun Kim | ![]() |
![]() |
|||
PB-1608 | Red blood cells transfusion can improve hemostatic dysfunction of Heyde Syndrome | Ayaka Kakiwaki | ![]() |
![]() |
|||
PB-1609 | Acquired thrombotic thrombocytopenic purpura occurring in advanced age: impact of a delayed onset on disease expression | Andrea Artoni | ![]() |
![]() |
|||
PB-1610 | Long-term Neuropsychological Sequelae, Emotional Wellbeing and Quality of Life in Patients with Acquired Thrombotic Thrombocytopenic Purpura | Ilaria Mancini | ![]() |
![]() |
|||
PB-1611 | ADAMTS-13 Inhibitor Testing Is often Negative on Initial Testing | Gloria Lim | ![]() |
![]() |
|||
PB-1614 | Potency Adjusted Bovine Heparin is Comparable to Porcine Heparin in Patients Undergoing Open Heart Surgery | Ahmed Kouta | ![]() |
![]() |
|||
PB-1616 | Enoxaparins Derived from Ovine (Sheep) Tissues Are Biosimilar to Branded Enoxaparin of Porcine (Pig) Origin | Tishya Indran | ![]() |
![]() |
|||
PB-1617 | Heparins Derived from Ovine (Sheep) Mucosa Are Interchangeable to their Porcine (Pig) Counterparts | Tishya Indran | ![]() |
![]() |
|||
PB-1618 | Bovine and Porcine Mucosal Heparins Exhibit Comparable Pharmacodynamic Behaviors at USP Potency Adjusted Doses | Ahmed Kouta | ![]() |
![]() |
|||
PB-1619 | Efficacy and Safety of Bronchial Artery Embolization on Hemoptysis in Chronic Thromboembolic Pulmonary Hypertension: A Pilot Prospective Cohort Study | Suqiao Yang | ![]() |
![]() |
|||
PB-1620 | The Independent Effect of Being a Strict Stockings Complier on the Outcome of the SOX Trial | Susan Kahn | ![]() |
![]() |
|||
PB-1621 | External Validation of the SOX-PTS Score (Clinical Prediction Model for the Post-thrombotic Syndrome) in a Prospective Multicenter Study of Patients with Proximal Deep Vein Thrombosis | Susan R Kahn | ![]() |
![]() |
|||
PB-1622 | Quality of Initial Anticoagulant Treatment is Not a Risk Factor for Developing Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism | Gudula J.A.M. Boon | ![]() |
![]() |
|||
PB-1623 | Contrast Enhanced Computed Tomography Has a High Sensitivity for Diagnosing Chronic Thromboembolic Pulmonary Hypertension | Eli Westerlund | ![]() |
![]() |
|||
PB-1626 | Can a 9-item modified villalta score adequately predict post thrombotic syndrome? A subgroup analysis from the ´Follow-up In Rivaroxaban patients in Setting of Thromboembolism´ (FIRST) Registry | Vicky Speed | ![]() |
![]() |
|||
PB-1627 | Initial thrombus above or below popliteal fossa is more predictive than residual thrombosis for postthrombotic syndrome after episode of deep venous thrombosis - RIETE experience with 1183 patients | Marijan Bosevski | ![]() |
![]() |
|||
PB-1628 | Sex-specific Differences in the Clinical Presentation, Surgical Complications, and Course of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Insights from the European CTEPH Registry | Stefano Barco | ![]() |
![]() |
|||
PB-1630 | Substantial Increase in Quality Adjusted Life Years by Earlier Diagnosis of Chronic Thromboembolic Pulmonary Hypertension | Gudula J.A.M. Boon | ![]() |
![]() |
|||
PB-1631 | Robotic assisted thrombotripsy allows high accurate venous recanalization in a porcine model of femoral venous thrombosis | Lina Khider | ![]() |
![]() |
|||
PB-1634 | Virchow´s Triad: Is it Applicable to Thrombosis of Mesenteric Vessels? | Bushra Moiz | ![]() |
![]() |
|||
PB-1635 | Utility of the DASH score after unprovoked venous thromboembolism: single centre study and long-term patient outcomes | Will Thomas | ![]() |
![]() |
|||
PB-1637 | An Exploration of the Psychological Impact of Pulmonary Embolism | Anna Tran | ![]() |
![]() |
|||
PB-1638 | Diagnostic Performance of Current Imaging Modalities for Diagnosing Cerebral Vein Thrombosis | Lisette F. van Dam | ![]() |
![]() |
|||
PB-1639 | Decline in Periprocedural Anticoagulant Use in Warfarin-treated VTE Patients Following the BRIDGE Trial Publication | Geoffrey Barnes | ![]() |
![]() |
|||
PB-1640 | Cost Savings Associated with Extended INR Testing Intervals | Scott Kaatz | ![]() |
![]() |
|||
PB-1641 | MAC Project - Monitoring Anticoagulant Therapy Observational Study - Rationale and Protocol | Giuseppe Camporese | ![]() |
![]() |
|||
PB-1642 | Absence of Interaction between Rivaroxaban, Tacrolimus and Everolimus in Renal Transplant Recipients Anticoagulated for Proximal Deep Vein Thrombosis or Atrial Fibrillation | Giuseppe Camporese | ![]() |
![]() |
|||
PB-1643 | Time in Therapeutic Range (TTR) of Ghanaian VTE Patients on Warfarin | Edeghonghon Olayemi | ![]() |
![]() |
|||
PB-1646 | MRDTI Can Distinguish Between Old and New Thrombosis in the Abdominal Aorta: A Case Report | Lisette F. van Dam | ![]() |
![]() |
|||
PB-1647 | Rationale for Clinicians to Hospitalize Patients with Acute Pulmonary Embolism: A Post-hoc Analysis of the Hestia and Vesta Studies | Stephan V. Hendriks | ![]() |
![]() |
|||
PB-1648 | Thrombogenic Potential in Patients Undergoing Hemodialysis Using Central Venous Catheter | Luci Dusse | ![]() |
![]() |
|||
PB-1649 | Single Centre Retrospective Review of Non-catheter Associated upper Extremity Deep Venous Thrombosis | Stephanie P´ng | ![]() |
![]() |
|||
PB-1650 | Birth of a coagulation clinic and its burden at the department of clinical hematology, Yangon General Hospital, Myanmar | Sein Win | ![]() |
![]() |
|||
PB-1652 | The role of anxiety and depression in the pathogenesis of thromboembolic events currently classified as unprovoked | Silvia Hoirisch-Clapauch | ![]() |
![]() |
|||
PB-1653 | Analysis of Central Venous Catheter Preservation on Prophylactic Rivaroxaban in the CASSINI Study | Gerald A. Soff | ![]() |
![]() |
|||
PB-1654 | Incidences of thrombosis, major bleeding and 30-day mortality in patients receiving veno-venous extracorporeal membrane oxygenation and value of laboratory parameters at presentation in predicting outcomes | Deepa Jayakody Arachchillage | ![]() |
![]() |
|||
PB-1656 | Treatment of PICC-related upper limb deep-vein or superficial vein thrombosis with Edoxaban. Rationale and protocol | Cristiano Bortoluzzi | ![]() |
![]() |
|||
PB-1657 | Identifying patient values and expectations for pulmonary embolism CT scanning in the emergency department | Vidushi Swarup | ![]() |
![]() |
|||
PB-1658 | Complication Rates after Upper Extremity Venous Thrombosis: a Systematic Review and Meta-analysis | Rick Ikesaka | ![]() |
![]() |
|||
PB-1659 | Thrombin Generation during Bleeding in Orally Anticoagulated Patients: Reversal Can Lead to Hypercoagulability | Aurélien Lebreton | ![]() |
![]() |
|||
PB-1660 | Cerebral Venous Thrombosis Risk Factors | Milan Kostal | ![]() |
![]() |
|||
PB-1662 | Recurrences after Splanchnic Vein Thrombosis: Risk Factors and Efficacy of Vitamin K-Antagonists in a Retrospective Monocenter Cohort of 207 Patients | Valerio De Stefano | ![]() |
![]() |
|||
PB-1663 | Extended INR Recall Interval in Patients with Stable INR - Real World Experience | Petr Kessler | ![]() |
![]() |
|||
PB-1664 | An easy-to-use tool to flag patients at risk of poor INR control: a streak of subtherapeutic INRs | Jasper H.A. van Miert | ![]() |
![]() |
|||
PB-1665 | Risk factors of Recurrences after Stopping Anticoagulant of First Non-Cancer Related Venous Thromboembolism in Thai Patients: A Prospective Cohort Study | Pitiphong Kijrattanakul | ![]() |
![]() |
|||
PB-1668 | Non hepatic causes of Adult Splanchnic Vein Thrombosis. A monocentric report of 24 cases | Zoubida Tazi Mezalek | ![]() |
![]() |
|||
PB-1669 | Interim analysis - Safety and efficacy of rivaroxaban in a patient population with short bowel syndrome; a prospective observational cohort study | Roisin Bavalia | ![]() |
![]() |
|||
PB-1670 | Incidence of venous thromboembolism in post-bariatric surgery patients | Feras Almarshad | ![]() |
![]() |
|||
PB-1671 | Influence of polymorphisms in the CYP2C9, VKORC1, MDR1 and APOE genes and other patient variables on warfarin dose in patients treated at anticoagulation clinics in Brazil | Luci Dusse | ![]() |
![]() |
|||
PB-1672 | Diagnostic accuracy of limited versus whole-leg ultrasonography for suspected deep vein thrombosis: a systematic review and meta-analysis | Noémie Kraaijpoel | ![]() |
![]() |
|||
PB-1673 | Brazilian version of the oral anticoagulation knowledge test: an item response theory approach | Luci Dusse | ![]() |
![]() |
|||
PB-1675 | Management of anticoagulant therapy around delivery: results from the ongoing Highlow study | Ingrid Bistervels | ![]() |
![]() |
|||
PB-1676 | A quality improvement program to reduce the use of inferior vena cava filters for unnecessary indications in a tertiary care center | Tzu-Fei Wang | ![]() |
![]() |
|||
PB-1677 | Safety and Efficacy of Full Dose Dabigatran in the Treatment of Deep Vein Thrombosis in a Very Young Adolescent | Franco Piovella | ![]() |
![]() |
|||
PB-1678 | Direct Oral Anticoagulant Laboratory Assay Assessment at a Large Academic Medical Center | Sharonlin Bhardwaj | ![]() |
![]() |
|||
PB-1679 | The CTPA Epidemic? | Sarah Kelliher | ![]() |
![]() |
|||
PB-1680 | Innovation in Interprofessional Education and Curriculum Development: A Simulation-based Anticoagulation Management Workshop for Hematology Trainees | Prakash Vishnu | ![]() |
![]() |
|||
PB-1682 | ISTH Guidelines and Apixaban Plasma Levels in Obese Patients | Marilyn Rees | ![]() |
![]() |
|||
PB-1687 | Antithrombin and D-dimer in Predicting Pregnancy Complications in the 3rd Trimester of Pregnancy | Ning Tang | ![]() |
![]() |
|||
PB-1690 | Assessment of the Knowledge about Venous Thromboembolism (VTE) on Pregnant Women Attending Kigali Referral Hospitals | Eva Hortas | ![]() |
![]() |
|||
PB-1692 | Effects of Low-dose Combined Oral Contraceptives and Protein S K196E Mutation on Anticoagulation Factors: A Prospective Observational Study | Toshiyuki Miyata | ![]() |
![]() |
|||
PB-1693 | Activated Partial Thromboplastin Time-based Unfractionated Heparin Dosing Protocol for Pregnant Patients | Reiko Neki | ![]() |
![]() |
|||
PB-1695 | Current ISTH Registries on Women´s Health Issues in Thrombosis and Haemostasis: Powerful Tools for Improved Data Collection and Outcome Measurement | Maha Othman | ![]() |
![]() |
|||
PB-1697 | High titer of false positive venereal disease research laboratory (f+VDRL) test among patients with Obstetric Antiphospholipid Antibodies Syndrome (OAPS) having triple positivity profile of antiphospholipid antibodies (aPL) | Silvia Perés | ![]() |
![]() |
|||
PB-1699 | Study of utilisation of combined hormonal contraceptives in Europe | Deeksha Khialani | ![]() |
![]() |
|||
PB-1703 | Transfusions during Pregnancy or Postpartum in 3 Italian Tertiary Level Obstetrics Departments: A Retrospective Analysis | Elvira Grandone | ![]() |
![]() |
|||
PB-1704 | Pulmonary Embolism in women transfused after postpartum hemorrhage: a single Centre audit | Elvira Grandone | ![]() |
![]() |
|||
PB-1705 | The Thromboelastography G Parameter as a Potential Marker for Coagulation Status Evaluation in Elderly Puerperant | Qiuya Lu | ![]() |
![]() |
|||
PB-1706 | Is Platelets Count Useful for Preeclampsia Diagnosis? | Luci Dusse | ![]() |
![]() |
|||
PB-1708 | Systemic Soluble Mediators in HELLP Syndrome Case Report | Luci Dusse | ![]() |
![]() |
|||
PB-1709 | The Challenges of Managing Severe Haemophilia A and Pregnancy in Same Sex Couples | Bella Madan | ![]() |
![]() |
|||
PB-1710 | Pregnancy, Childbirth and Neonatal Outcomes in Women with Inherited Bleeding Disorders | Lisa Clarke | ![]() |
![]() |
|||
PB-1712 | A model for the dual actions of plasminogen activator inhibitor type-2 (PAI-2) during oxidative stress | Jordan Cater | ![]() |
![]() |
|||
PB-1714 | Is the Resolution of Inflammation Altered in Preeclampsia? | Luci Dusse | ![]() |
![]() |
|||
PB-1715 | An obstetric thrombophilia patient with heterozygous factor V Leiden (A1691G) and homozygous C677T MTHFR mutations in family history; case report and literature review | Justyna Teliga-Czajkowska | ![]() |
![]() |
|||
PB-1716 | Outcome of Pregnancies Inadvertently Conceived during Rivaroxaban Anticoagulation Therapy - Case Series | Justyna Teliga-Czajkowska | ![]() |
![]() |
|||
PB-1718 | The impact of glycemic control in pregnant women with gestational and pregestational diabetes on coagulation status and lipid metabolism | Justyna Teliga-Czajkowska | ![]() |
![]() |
|||
PB-1719 | Inherited Thrombophilia in Infertility Patients in Macedonia | Elena Petkovikj | ![]() |
![]() |
|||
PB-1722 | Platelet indices and cardiovascular events: prospective findings from the CAMELIA study | Gian Marco Podda | ![]() |
![]() |
|||
PB-1724 | Gene Therapy Knowledge and Perceptions: Results of an International ISTH Survey | K. John Pasi | ![]() |
![]() |
July 6-10, 2019 Melbourne
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|